AP637A - Heterocyclic ring-fused pyrimidine derivatives. - Google Patents

Heterocyclic ring-fused pyrimidine derivatives. Download PDF

Info

Publication number
AP637A
AP637A APAP/P/1996/000805A AP9600805A AP637A AP 637 A AP637 A AP 637A AP 9600805 A AP9600805 A AP 9600805A AP 637 A AP637 A AP 637A
Authority
AP
ARIPO
Prior art keywords
pyrimidin
amine
pyrido
phenyl
pyrrolo
Prior art date
Application number
APAP/P/1996/000805A
Other versions
AP9600805A0 (en
Inventor
Lee Daniel Arnold
Mikel Paul Moyer
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600805A0 publication Critical patent/AP9600805A0/en
Application granted granted Critical
Publication of AP637A publication Critical patent/AP637A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A compound of the formula

Description

HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES
Background of the Invention
This invention relates to heterocyclic ring-fused pyrimidine derivatives and methods of using the same in the treatment of hyperproliferative diseases, such as cancers and psoriasis; restenosis; kidney disease and pancreatitis and for preventing biastocyle implantations, e.g. contraception, in mammals.
Many of the current treatment regimes for cancer utilize compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on the rapidly dividing tumor cells can be beneficial. Alternative approaches to anticancer agents which act by mechanisms other than the inhibition of DNA synthesis have been explored in order to enhance the selectivity of action against cancer cells.
It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e. a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins which are aberrant tyrosine kinases capable of causing cell transformation. Alternatively, the overexpression of a normal proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype.
Receptor tyrosine kinases are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer. It has also been shown that epidermal growth factor receptor (EGFR) which possesses tyrosine kinase activity is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors.
Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as a selective inhibitors of the growth of mammalian cancer cells. For example, erbstatin, a tyrosine kinase inhibitor selectively attenuates the growth in athymic nude mice of a transplanted human mammary carcinoma which expresses
S 0 8 0 n ' 9 6 /d/dV
AP 00637
-2epidermal growth factor receptor tyrosine kinase (EGFR) but is without effect on the growth of another carcinoma which does not express the EGF receptor.
Various other compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties. More recently three European patent publications, namely EP 0 566 226 A1, EP 0 602 851 A1 and EP 0 520 722 A1 have disclosed that certain heteroaryl-fused pyrimidine derivatives possess anti-cancer properties which result from their tyrosine kinase inhibitory properties. Also PCT publication WO 92/20642 discloses bis-mono and bicyciic aryl and heteroaryl compounds as tyrosine kinase inhibitors.
European patent publication EP 0 496 617 A1 discloses certain pyrazolo[3,4djpyrimidines and pyrrolo[2,3-d]pyrimidines which possess adenosine kinase inhibitory properties.
European patent publication EP 0 475 413 A2 discloses certain carbocyclic nucleoside analogs as useful immunosuppressants.
European patent publication EP 0 414 386 A1 discloses certain pyrido[2,3djpyrimidines as fungicides, insecticides and miticides. The synthesis and antiallergic activity of 9-aryl-8-azaadenine derivatives is described in II Farmco-Ed. Sc., vol 35, fasc. 4 p308-323 (1980).
Co-pending United States patent applications (United States Serial Nos.
08/200,359 and 08/413,300) and PCT application docket no. PC8836A, assigned to the
Assignee of this application, describe optionally substituted indolyl- and phenylamino quinazolines, respectively, which are useful in the treatment of hyperproliferative diseases involving receptor tyrosine kinases. In addition U.S. Patent No. 4,012,513 discloses certain 1-(heterocyclic)-indol-3-yl-acetic acid derivatives that have anti25 inflammatory, analgesic and antipyretic activity.
Although the anti-cancer compounds described above make a significant contribution to the art there is a continuing search in this field of art for improved anticancer pharmaceuticals.
Summary of the Invention
AP/P/ 9 6/60805
This invention is directed to compounds of the Formula
AP 00637
and stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Y together with the carbons to which it is attached form a 5 or 6 membered, aromatic ring wherein said ring is optionally substituted with (R3)p and/or R4 groups and comprises one to three nitrogens and optionally one heteroatom selected from S and
O;
Zis NR’R2 wherein R1 is H and R2 is phenyl substituted by (R5)m or Q or R’R2N is a group of the formula (R6)^
AD/D/ c fi / fn’, fl n R wherein the dotted line represents an optional double bond;
each R3 is attached to a carbon atom in Y and is independently selected from
a. phenyl, trifluoromethyl, halo, nitro, hydroxy, amino, cyano, (C^CJalkyl, (C,CJalkoxy, (C^CJalkoxycarbonyl, (C,-C4)alkanoyloxy, (C^-CJalkanoylamino, carboxy, phenoxy, benzoyloxy, carbamoyl, mono-N-ordi-N-N-di-(C,-C4)alkylcarbamoyl, mono-N30 or di-N,N-(C,-C4)alkylamino, mono-N or di-N,N-(hydroxy(C2-C4)alkyl)amino, mono-N or di-N.N-^C^CJalkoxyfCj-CJalkylJamino, anilino, pyrrolidin-1 -yl, piperidin-1-yl, morpholino, piperazin-1-yl, A-fC^CJaikylpiperazin-l-yl, pyridyl, pyrrolo, imidazolo,
AP Ο Ο β 3 7 thiazolo, benzimidazolo, pyridonyl, (C^CJaikylthio, phenytthio, or such groups substituted on (C,-C4)aikyl;
b. hydroxy(C2-C4)alkoxy(C,-C4)alkyl, (C,-C4)alkoxy-(C2-C4)alkoxy-(C,-C4)alkyl, hydroxy(C2-C4)alkylthio(C,-C4)alkyl, (C1-C4)alkoxy(C2-C4)alkylthio(C,-C4)alkyl, hydroxyamino, benzoylamino, mono-N or di- N.N-iC^CJalkylcarbamoylmethylamino, carbamoylmethylamino, (C,-C4)alkoxycarbonylamino, (C,-C4)alkanoylamino, carboxymethylamino, (C,-C4)alkoxycarbonylmethylamino, (C1-C4)alkoxyamino, (C2CJalkanoyloxyamino, phenyKC^CJalkylamino, (C^CJalkylsulphonylamino, benzenesuiphonamido, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, ureidoXC^CJalkoxytCj-CJalkylcarbonylaminoXCj-CJalkylsulfinylXC^CJalkylsulfonyl, (C^-CJalkoxyiCj-CJalkylthio, mono-, di- or trifluoromethyloxy, (C,-C4)alkyienedioxy, benzyloxy, guanidino, aminocarbonyl, mono-N- or di-N,N-(C,-C4)aikylaminocarbonyl, phenyl(C,-C4)alkoxy, carboxymethoxy, (C,-C4)alkoxycarbonylmethoxy, carbamoylmethoxy, mono-N or di-N.N-iCpCJalkyl carbamoylmethoxy, mono-N- or di15 N,N-(hydroxy(C2-C4)alkyl)carboxamido, mono-N- or di-N.N-^C^-CJalkoxy (C2C4)alkyl)carboxamido or bis((C,-C4)alkanesuifonyl)amido; or
c. (C2-C4)alkoxy, (C2-C4)alkylthio, (C2-C4)alkanoyloxy, (C2-C4)alkylamino, (C,CJalkyltCj-CJalkylenedioxy, (C2-C4)aikanoylamino, (C2-C4)alkenyl, or (C2-C4)alkynyl; each such group substituted with amino, halo, hydroxy, (C2-C4)alkanoyloxy, (C,20 C4)alkoxy, mono-N- or di-N.N-^-CJalkylamino, mono-N or di-N,N-(hydroxy(C2C4)alkyl)amino, mono-N or di-N,N-((C,-C4)alkoxy(C2-C4)alkyl)amino, (C,C4)alkanoylamino, phenoxy, anilino, imidazol-1-yl, phenytthio, piperidino, pyridyl, carboxy(C1-C4)alkylthio(C,-C4)alkoxy, morpholino, piperazin-1 -yl-, 4-(C,C4)alkylpiperazin-1-yl-, carboxy, (C,-C4)alkoxycarbonyl, carbamoyl, mono-N-or di-N,N25 (Cj-CJalkylcarbamoyl, carboxamido, mono-N- or di-N,N-(C,-C4)alkylcarboxamido or mono-N- or di-N,N-(hydroxy(C2-C4)alkyl)carboxamido; and any phenyl in an R3 substituent is optionally mono- or di- substituted with halo, nitro, trifluoromethyl, hydroxy, (C,-C4)alkoxy, (C^CJalkyl, amino, mono-N-alkylamino, or N,N-dialkylamino;
R* is attached to a N-atom in Y and is independently selected from:
hydrogen, (CT-CJalkyl, (C^CJaikoxycarbonyl, (C,-C4)alkanoyl, (C^-CJalkylsulfonyl, arylsuifonyl, allyl; or a (C2-C4)alkyl, (C2-C4)aikanoyl, or (C2-C4)alkoxycarbonyl, (C2C4)alkylsulfonyl, each such group substituted with amino, halo, hydroxy, (C2C4)alkanoyloxy, (C,-C4)alkoxy, mono-N-or di-N,N-(C,-C4)alkylamino, mono-N or di-N,NAP/P/ 96/00805
AP 00637
-5(hydroxy(C2-C4)alkyl)amino, mono-N or di-N,N-((C,-C4)alkoxy(C2-C4)alkyl)amino, (C,C4)alkanoylamino, phenoxy, anilino, imidazol-1-yl, phenylthio, piperidino, morpholino, piperazin-1-yl-, 4-(C,-C4)alkylpiperazin-1-yl-, phenyl, pyridyl, pyrrolo, imidazolo.thiazolo, benzimidazolo, pyridonyl, carboxy, (C^-CJalkoxycarbonyl, carbamoyl, mono-N- or di5 N,N-(C,-C4)alkylcarbamoyl, carboxamido, mono-N- or di-N.N-fC^CJalkylcarboxamido or mono-N- or di-N,N-(hydroxy(C2-C4)alkyl)carboxamido; and any phenyl in an R4 substituent is optionally mono- or di- substituted with halo, nitro, trifluoromethyi, hydroxy, (C,-C4)alkoxy, (C,-C4)alkyl, amino, mono-N-alkylamino, or N,N-dialkylamino; but specifically R4 is not furanosyi, pyranosyl, or cyclopentyl;
each R6 is independently selected from mono-, di- or tri-fluoromethyl, halo, nitro, hydroxy, amino, azido, isothiocyano, (Ο,-CJalkyl, phenyl, thienyl, (C,-C4)alkoxy, benzyloxy, phenoxy, (C2-Ce)alkenyl, (C2-Ce)alkynyl, (C1-C4)alkylenedioxy, cyano, benzoylamino.trifluoromethylcarbonylamino, (C,-C4)alkanoylamino, (C,-C4)alkanoyl, Nmono- or N,N-di-(C,-C4)aIkylamino, (C,-C4)alkylsulfonylamino, frifluoromethylsulfonylamino, (C^CJalkylthio, (C,-C4)alkyisulfinyl or(C,-C4)aikylsulfonyl, pyrrol-1-yl, piperidin-1 -yl or pyrrolidin-1-yl, said phenyl, benzyloxy, phenoxy and benzoylamino optionally mono-substituted with halo, nitro, trifluoromethyi, hydroxy or (Ο,-CJalkyl and said (C1-C4)alkyienedioxy is linked at both ends to adjacent carbons on the benzene moiety or two R5,s with the carbons atoms to which they are attached form a group selected from imidazolyl, pyrrolo and pyrazolyl;
each Re is independently selected from hydroxy, amino, N-mono- or N,N-di-(C,•S C4)alkylamino, sulfo, or (C,-C4)alkoxy (provided that such groups are not attached to a ring carbon which is directly adjacent to the ring N-), or R8 for each occurrence is independently carboxy, hydroxyiC^CJaikyl, (C^CJalkoxyfC^CJalkyl, aminoiC^25 C4)alkyl, mono-N- or di-N,N-(C1-C4)alkylamino(C1-C4)alkyl, morpholino (C^CJalkyl, 4(C,-C4)alkyl-piperazin-1 -yl(C, -C4)alkyl, carboxyiC^CJalkyl, (C^CJalkoxycarbonyl, sulfo^-CJalkyl, pyridyl(C,-C4)alkyl or (C,-C4)alkyl;
m is an integer from 1 to 3; n is 0, 1 or 2;
p is 0 or an integer from 1 -3;
with the proviso that when Y, in the direction shown by the arrow in formula I, is -CR3=N-CR3=CR3-, p = 0, m = 1 and Z is substituted phenyl then R5 is not 4ethoxy, 4-methoxy, 4-trifluoromethoxy, 4-t-butyl or 4-isopropyl;
u o v v r j 'j ruruv
AP 00637
-6Q is a 9- or 10-membered bicyclic heteroaryl moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (C,-C4)alkyl, (C,-C4)alkoxy, (CrC4)alkylamino, di-KC^CJalkylJamino, and (C2-C4)alkanoyiamino; with the proviso that when Y, in the direction shown by the arrow in formula I, is -NR4-CR3=CR3-, R3 = CH3 and R*=H, then R5 is not 4-CH3, 3,5-(CH3)2, 2,6-(CH3)2, 2-C2Hb, 4-C2Hb, 4-n-C4H9, 2-CI, 4-CI, 3,4-CI2, 2-F, or 3-CF3.
According to another aspect of the invention there is provided a compound as 10 described above wherein Y, in the direction shown by the arrow in formula I, is selected from -N=CR3-NR4-, -CR3=CR3-NR4-, -NR4-CR3=CR3-, -N=N-NR4-, -NR4-N=N-, -CR3=NNR4-, NR4-N=CR3, =CR3-NR4-CR3=, -N=CR3-CR3=CR3-, -CR3=N-CR3=CR3-, CR3=CR3-N=CR3-, -CR3=CR3-CR3=N-.
Another aspect of the invention provides a compound as described above 15 wherein each R3 is independently selected from hydroxy, (C,-C4)aJkoxy, hydroxy(C2C4)alkoxy, amino(C2-C4)alkyl, amino(C2-C4)alkoxy, (C,-C4)aIkoxy(C2-C4)alkoxy, hydroxy(C, -CJaJkylfC, -CJalkylenedioxytC, -CJalkoxyiC, -CJalkyl (C, -C4)alkylenedioxy, mono-N- or di-N,N-(C,-C4)alkylamino(C2-C4)alkoxy, 3- or 4-(C,-C4)alkoxy-(2-hydroxy)(C3-C4)aikoxy, carboxy(C1-C4)aIkoxy, morpholino(C2-C4)alkoxy, imidazol-1-yl(C220 C4)alkoxy, AiC^CJaikylpiperazin-l-yl-fCj-CJalkoxy, (C^CJalkoxyfC^CJaikanoyloxy, nitro, hydroxylamino, amino, phenyl, pyridyl, pyrrolo, imidazolo, thiazolo, benzimidazole, pyridonyl, mono-N- or di-N.N-fC^CJalkylamino, (C,-C4)alkanoyiamino, hydroxy(C2C4)alkyiamino, (C,-C4)alkoxy(C2-C4)alkylamino, (C^CJalkylsulfonamido, morpholino, (C,-C4)aikyl-piperazin-1-yl, bis(C,-C4)alkanesulfonamido, di-N.N-fC^CJalkylaminoiCj25 C4)alkylamino, (C,-C4)alkylamino(C2-C4)alkylamino, piperidin-1-yl, imidazol-1-yl, pyrrolidin-l-ylJCj-CJaikoxyiCJ-CJalkylcarbonylamino.carboxyJC^-CJalkoxy carbonyl, (C1-C4)aikoxycarbonyl(C1-C4)alkoxy, amido, mono-N- or di-N,N(C,-C4)aJkylaminocarbonyl. mono-N- or di-N,N-(hydroxy(C2-C4)alkyl)aminocarbonyl, (C1-C4)alkyl, hydroxy(C,-C4)alkyl, mono-N- or di-N,N-((C1-C4)alkoxy(C130 C4)alkyl)amino(C,-C4)alkyl, mono-N- or di-N,N-(CrC4)alkylamino(C,-C4)alkyl, (C, -C4)alkanoylamino(C, -C4)alkyl, (C, -CJalkoxyiCj-CJalkoxyfC, -C4)alkyl, (C, C4)alkylthio, (C,-C4)alkoxy(C2-C4)alkylthio or hydroxy(C2-C4)alkylthio; and R4 is selected from hydrogen, benzyl, phenyl, a (C2-C4)alkyl, hydroxy(C2-C4)alkyl, or hydroxy(C2S 0 8 9 0 / 96 /d/dV
AP 00637
-7C4)alkyl, amino(C2-Ce)alkyl, (C2-C4)alkoxycarbonyl each such group substituted with amino, halo, hydroxy, (C2-C4)alkanoyloxy, (C,-C4)alkoxy, mono-N- or di-N,N-(C,C4)alkylamino, mono-N or di-N,N-(hydroxy(C2-C4)alkyl)amino, mono-N or di-N,N-((C,C4)alkoxy(C2-C4)alkyl)amino, sulfonylaryliC^CJalkylamine, (C,-C4)alkanoylamino, imidazol-1-yl, piperidino, morpholino, piperazin-1-yl-, 4-(C,-C4)alkylpiperazin-1-yl-, pyridyl, pyrrolo, imidazolo, thiazolo, pyridonyl, carboxy, (C,-C4)alkoxycarbonyl, carbamoyl, mono-N-or di-N,N-(C,-C4)alkylcarbamoyl, carboxamido, mono-N- ordi-N,N(C1-C4)alkylcarboxamido or mono-N- or di-N,N-(hydroxy(C2-C4)a!kyl)carboxamido.
Yet another aspect of the invention provides a compound as described above wherein Y in the direction shown by the arrow in formula I, is selected from -CR3=CR3NR4-, -NR*-CR3=CR3- and -CH=CR3-N=CH-.
According to another aspect of the invention there is provided a compound as described above wherein Y, in the direction shown by the arrow in formula I, is selected from -NR*-CR3=CR3-, or -CH=CR3-N=CH- and -CR3=CR3-NR*-.
Yet another aspect of the invention provides a compound as described above wherein Y, in the direction shown by the arrow in formula I, is -CR3=CR3-NR4- and R4 is hydrogen.
Another aspect of the invention provides a compound as described above wherein R'R2N is
Ll e
t c
ς c
»» c
and R5, R®, m and n are as defined above.
According to another aspect of the invention there is provided a compound as described above wherein each R5 is independently selected from 4-hydroxy, 4-amino, 5-fluoro, 5-hydroxy, 5-amino, 6-halo, 6-methyl, 6-ethenyl, 6-ethynyl, 6-nitro and 7-methyl and each R® is independently selected from hydroxy, amino, N-mono- or N.N-di-iC,C4)alkylamino, sulfo, or (Ο,-CJalkoxy (provided that such groups are not attached to a ring carbon which is directly adjacent to the ring N-), or R® for each occurrence is independently carboxy, hydroxyiC^CJalkyl, (C^CJalkoxyiC^CJalkyl, amino(C,AP 00637
-8C4)alky1, mono-N- or di-N.N-iC^CJalkylaminofC^CJaikyi, morpholino (C,-C4)alkyl, 4(C,-C4)aIkyl-piperazin-1 -yl(C,-C4)alkyl, carboxy^-C4)alkyl, (C^CJalkoxycarbonyl, sulfoiC^CJalkyl, pyridyl (C,-C4)alkyl and (C,-C4)alkyl.
Another aspect of the invention provides a compound as described above 5 wherein R1 is H and R2 is (R5)m-substituted phenyl wherein R5 and m are as defined above.
Yet another aspect of the invention provides a compound as described above wherein each R5 is independently selected from 4-fluoro-3-chloro, 3-trifluoromethyl, 4fluoro-3-trifluoromethyl, 3-nitro-4-chloro, 3-nitro-4-fluoro, 4-fluoro-3-bromo, 3-iodo-510 amino, 3-methyl-4-fluoro, 4-amino, 3-fluoro, 3-hydroxy, 3-amino, 3-halo, 3-methyl, 3ethenyl, 3-ethynyl, 3-nitro and 4-methyl.
According to another aspect of the invention there is provided a compound as described above wherein R’ is H and R2 is Q.
Another aspect of the invention provides a compound as described above 15 wherein Q is selected from pyrrolo, 4-, 5-, 6-indolyl, 1H-benzimidazol-4-yl, 1Hbenzimidazol-5-yl, 1 H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, 1 H-indazol-7-yl, 1Hbenzotriazol-4-yl, 1 H-benzotriazol-5-yl, 1H-benzotriazol-6-yl, 5- or 6-benzoxazolyI, 5- or
6-benzothiazolyl, benzo[c][2,1,3]thiadiazol-4-yl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-,
4-, 5-, 6-, 7- or 8-isoquinolyl, 4-, 5-, 6-, 7- or 8-cinnolinyl, 5-, 6-, 7- or 8-quinazolinyl, or
2-, 5-, or 6-quinoxalinyl, which may optionally bear one or two substituents selected from fluoro, bromo, chloro.methyl, ethyl, ethenyl, ethynyl and methoxy.
Yet another aspect of the invention provides a compound as described above wherein Q is selected from pyrrolo 5-indolyi, 1H-indazol-5-yl, 1 H-benzotriazol-5-yl, 6benzothiazolyi, benzo [c] [2,1,3]thiadiazol-4-yl, 5-quinolyl, 6-quinolyl, 8-quinolyl, 525 isoquinolyl, or 5-quinoxalinyl, which may optionally bear one or two substituents selected from fluoro, bromo, chloro.methyl, ethyl, ethenyl, ethynyl and methoxy.
Preferred compounds of formula i are selected from the group consisting of (3-ethynyl-phenyl)-(7H-pyrrolo[2,3-dlpyrimidin-4-yl)-amine hydrochloride;
(3-chloro-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine hydrochloride;
4-(6-chloro-2,3-dihydro-indol-1 -yl)-7H-pynrolo[2,3-d]pyrimidine hydrochloride;
(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-m-tolyl-amine hydrochloride;
(1 H-indol-5-yl)-(7H-pyrrolo[2,3-d)pyrimidin-4-yl)-amine hydrochloride;
(6-methylindolin-1-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
AP/Pi 9 6 / 0 0 8 0 5
AP 00637
-9(benzo[b]thien-5-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yI)-amine;
(6-chloro-5-fluoroindolin-1-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
(1 H-indazol-5-yI)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
1-(4-m-tolylamlno-pyrrolo[2,3-d]pyrimldin-7-yl)-ethanone hydrochloride;
(5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-m-tolyl-amine;
(3-chloro-phenyl)-(1 H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-amine hydrochloride;
(3- chloro-phenyl)-pyrido[4,3-d]pyrimidin-4-yl-amine hydrochloride;
(1 H-indol-5-yl)-pyrido[4,3-d]pyrimidin-4-yl-amine hydrochloride;
(3-ethynylphenyl)-(7-methyl-pyrido[4,3-d]pyrimidin-4-yl)-amine hydrochloride;
(3-chloro-phenyl)-(7-methyl-pyrido[4,3-d]pyrimidin-4-yl)-amine hydrochloride;
(S-ethynyl-phenylMpyrido^.S-dlpyrimidin-A-yO-amine hydrochloride; (6-bromo-5-fluoroindolin-1-yl)-(pyrido[4,3-<i]pyrimidin-4-yl)-annine; ** (6-chloro-5-fluoroindolin-1-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine; C β
(1 H-indazol-5-yl)-(pyrido[4,3-d]pyrimidin-4-yi)-amine;
(3-methyl-4-hydroxyphenyl)(6-methylpyrido[4,3-d]pyrimidin-4-yl)-amine; C (6-iodoindolin-1-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine; (benzo[b]thien-5-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine; (3-ethynyl-phenyl)-(9H-purin-6-yl)-amine;
(1 H-indol-5-yl)-(9H-purin-6-yl)-amine hydrochloride;
(3-chloro-phenyl)-(9H-purin-6-yl)-amine hydrochloride;
4-(6-chloro-2,3-dihydro-indol-1-yl)-pyrido[3,4-d]pyrimidine;
(pyrido [3,4-d] pyrimidin-4-yI)-(m-tolyl)-amine;
(1 H-indazol-5-yl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine;
(1 H-indol-5-yl)-(pyrido [3,4-d] pyrimidin-4-yl)-amine;
(phenyl)-(pyrido[2,3-d]pyrimidin-4-yl)-amine;
(3-chloro-phenyl)-(pyrido[2,3-d]pyrimidin-4-yl)-amine; (3-chloro-phenyl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine; (3-bromo-phenyl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine;
(phenyl)-(pyrido [3,4-d] pyrimidin-4-yl)-amine;
4-(6-chloro-2,3-dihydro-indol-1 -yl)-pyrido[3,4-d]pyrimidine;
(pyrido[3,4-d]pyrimidin-4-yl)-(m-tolyl)-amine;
(1H-indazol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
(1H-indol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
ys /a/av
AP 00637
-10phenyl-pyrido[2,3-d]pyrimidin-4-yl-amine;
(3-chloro-phenyl-pyrido [2,3-d] pyrimidin-4-yl-amine; (3-chloro-phenyl-pyrido[3,4-d]pyrimidin-4-yl-amine; (3-bromo-phenyl-pyrido[3,4-d]pyrimidin-4-yl-amine;
phenyl-pyrido [3,4-d] pyrimidin-4-yl-amine;
(7-benzenesulfonyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine;
4-(6-chloro-2,3-dihydro-indol-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-ol;
(3-ethynyl-phenyl)-[7-(2-morpholin-4-yl-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
(3-ethynyl-phenyl)-[7-(2-methoxy-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
(3-ethynyl-phenyl)-{7-[2-(2-methoxy-ethoxy)-ethyl] -7H-pyrrolo [2,3-d] pyrimidin-4yl}-amine;
(7-allyl-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine hydrochloride; (3-ethynyl-phenyl)-(7-methyl-pyrrolo[2,3-d]pyrimidin-4-yl)-amine hydrochloride;
(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine;
(3-ethynyl-phenyl)-(5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
4-(3-ethynyl-phenylamino)-7H-pyrrolo [2,3-d] pyrimidine-5-carboxylic acid; (3-ethynyl-pheny1)-(5-methyi-7H-pyrrolo[2,3-d]pyrimidin-4-y1)-amine hydrochloride; N-(5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-m-tolyl-acetamide;
4-(3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid methyl esterhydrochloride;(3-ethynyl-phenyl)-(5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
(1H-indazol-5-yI)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride; benzo[b]thiophen-5-yl-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)- amine hydrochloride;
(3-ethynyl-4-fluoro-phenyl)-(6-methyl-pyiido[3,4-d]pyrimidin-4-yl)-amine;
2-methyl-4-(6-methyl-pyrido[3,4-d]pyrimidin-4-ylamino)-phenol dihydrochloride;
4-(4-bromo-7-methyl-2,3-dihydro-indol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine hydrochloride;
4-(6-bromo-7-methyl-2,3-dihydro-indol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine hydrochloride;
4-(6-bromo-5-fluoro-2,3-dihydro-indol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine hydrochloride;
(3-chloro-4-fluoro-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
AP/P/ 96 / 0 080 5
AP 00637
-11(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-(3-trifluoromethyl-phenyl)-amine hydrochloride;
(4-fluoro-3-methyl-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
2-iodo-4-(6-methyl-pyrido[3l4-d]pyrimidin-4-ylamino)-phenol hydrochloride;
(4-bromo-3-fluoro-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
4-(6l7-dimethyl-2,3-dihydro-indol-1-yl)-pyrido[3,4-d]pyrimidine hydrochloride; (3-ethynyl-phenyl)-pyrido[3,4-d]pyrimidin-4-yl-afnine hydrochloride;
benzo[b]thiophen-5-yl-pyrido[3,4-d]pyrimidin-4-yl-amine hydrochloride;
(3-ethynyl-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride; 4 (6-chloro-2,3-dihydro-indol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine;
(3-ethynyl-phenyl)-(5-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;and (1H-indol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine methanesulfonate.
Most preferred compounds of the formula I as described above are selected from (1H-indol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
(3-ethynyl-phenyl)-(6-methyl-pyrido [3,4-d] pyrimidin-4-yl)-amine; ( *
(3-ethynyl-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; £ (3-chloro-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; * (3-ethynyl-phenyl)-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- amine; 4-(3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylicacid methyl ester;
4-{3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbon'rtrile;
{1 H-indol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
(3-chloro-4-fluoro-phenyl)-(5-methyl-pyrido [3,4-d] pyrimidin-4-yl)- amine; benzo [b]thiophen-5-yl-(6-methyl-pyrido [3,4-d] pyrimidin-4-yl)-amine; (3-ethynyl-phenyl)-pyrido [3,4-d] pyrimidin-4-yl-amine;
(4-fluoro-3-methyl-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)- amine;
4-(6-chloro-2,3-dihydro-indol-1-yl)-pyrido[3I4-d]pyrimidine;
pyrido [3,4-d] pyrimidin-4-yl-m-tolyl-amine;
(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-(3-trifluoromethyt-phenyl)- amine;
(1H-indazol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
AP 00637
-12(3-ethyny1-phenyl)-(5-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; (1 H-indol-5-y1)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; (5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine;
The invention also provides a compound of the formula
I I wherein W, in the direction indicated by the arrows, is selected from =CHC(CH3)NCH=, -CH=N-C(CH3)=CH-and =C(CH3)-NH-CH= and the dotted circle indicates that the ring is aromatic.
According to another aspect of the invention there is provided a compound as described above wherein W is -CH=C(CH3)-N=CH-.
Another aspect of the invention provides a compound as described above wherein W is -CH2=N-C(CH3)=CH-.
Yet another aspect of the invention provides a compound as described above wherein W is =C(CH3)-NH-CH=.
The invention also provides a method of treating hyperproliferative disorders which comprises administering to a mammal in need of such treatment a hyperproliferative disorder treating amount of a compound of formula I.
According to another aspect of the invention there is provided a method as described above wherein the hyperproliferative disease is cancer.
Yet another aspect of the invention provides a method as described above wherein the disease is brain, lung, squamous cell, bladder, gastric, pancreatic, hepatic, renal, colorectal, breast, head, neck, oesophageal, gynecological or thyroid cancer.
Another aspect of the invention provides a method as described above wherein the hyperproliferative disorder is noncancerous.
AP/P/ »6/00805
AP 00637
-13Another aspect of the invention provides a compound as described above wherein the noncancerous hyperproliferative disorder is psoriasis or benign prostatic hyperplasia.
The invention further provides a pharmaceutical composition for the treatment 5 of hyperproliferative disorder in a mammal which comprises a hyperproliferative disease treating amount of a compound of formula I and a pharmaceutically acceptable carrier.
In the present application certain terms are defined as follows:
By halo is meant chloro, bromo, iodo, or fluoro.
By alkyl is meant straight chain or, when C3 or larger, a cyclic or branched 10 optionally unsaturated hydrocarbon.
As used herein, the expression reaction-inert solvent* refers to a solvent which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
Other features and advantages will be apparent from the specification and 15 claims which describe the invention.
Detailed Description of the Invention
The Formula I compounds, or pharmaceutically acceptable salts and prodrugs thereof can be prepared by any process known to be applicable to the preparation of chemically-related compounds.
AP u 0 6 3 7
-14SCHEME
I
AP/P/ 96/00805
AP 00637
-15As shown in the Scheme the Formula I compounds can, generally, be made prepared from the 4-chloro or hydroxy derivatives of the appropriately substituted heteroaryl-fused pyrimidine 1 using the appropriately substituted amine ZH 2.
Typically the appropriately substituted 4-haloheteroaryl-fused pyrimidine 1 (or 5 a heteroaryl-fused pyrimidine bearing a suitable displaceable leaving group in the 4position such as aryloxy, alkyl sulfinyloxy such as trifiuoromethanesutfonyloxy, arylsutfinyloxy, siloxy, cyano, pyrazolo, triazolo ortetrazolo), preferably a haloheteroaryl such as 4-chloroheteroaryl derivative, is reacted with the appropriate amine 2 in a solvent such as a (C^CeJalcohol, dimethylformamide (DMF), N-methylpyrroiidin-2-one, chloroform, acetonitrile, tetrahydrofuran (THF), dlmethylsulfoxide (DMSO), 1 -4 dioxane, pyridine or other aprotic solvent. The combination can be effected in the presence of a base, preferably an alkali or alkaline earth metal carbonate or hydroxide or a tertiary amine base, such as pyridine, 2,6-iutidine, collidine, N-methyl-morpholine, triethylamine, u c
diethyl isopropyl amine, 4-dimethylamino-pyridine or Ν,Ν-dimethylaniline. These bases c are hereinafter refered to as suitable bases*. The mixture is maintained at a C temperature of from ambient to reflux, preferably from about 35°C to reflux, until substantially no remaining 4-haloheteroaryl-fused pyrimidine can be detected, typically about 2 hours to about 72 hours. The reaction is preferably performed under an inert atmosphere such as dry nitrogen gas. In the case of pyrrolopyrimidines, it is preferable to carry out the reaction in CH3OH at temperature of about 90-140°C in a sealed tube in the absence of additional base.
Generally, the reactants are combined stoichiometrically when a suitable amine base is used, although, for those compounds where a salt (typically the HCI salt) of the amine is used, it is preferable to use excess amine 2, generally an extra equivalent of the amine 2. Alternatively, if an amine base is not used an excess of the amine reactant may be used)
For those compounds where a sterically hindered amine (such as a 2-alkylindoline) or very reactive 4-haloheteroaryl-fused pyrimidine is used it is preferable to use t-butyl alcohol or a polar aprotic solvent such as dimethylformamide or N30 methylpyrrolidin-2-one as the solvent.
Other Formula I compounds may be prepared by the following appropriate reactions subsequent to the above coupling.
j u fafav
AP 00637
-16Compounds of Formula I wherein R3 or R® is a primary amino or hydroxyamino may be prepared by the reduction of Formula I compounds wherein R3 or R® is a nitro group.
The reduction may conveniently be carried out by any of the many procedures 5 known for such transformations. The reduction may be carried out, for example, by the hydrogenation of a solution of the nitro compound in a reaction-inert solvent in the presence of a suitable metal catalyst such as palladium or platinum. A further suitable reducing agent is, for example, an activated metal such as activated iron (produced by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be carried out by heating a mixture of the nitro compound and the activated metal in a solvent such as a mixture of water and an alcohol, for example, methanol or ethanol, to a temperature in the range, for example, 50 to 150°C, conveniently at or near 70°C.
For the production of those compounds of Formula I wherein R® or R® incorporates a primary or secondary amino moiety (other than the amino group intended to react with the quinazoline), such free amine is preferably protected prior to the above described reaction followed by deprotection, subsequent to the above described reaction with 4-haloquinazoline.
For a description of protecting groups and their use, see T.W. Greene and
P.G.M. Wuts, Protective Groups in Organic Synthesis Second Ed., John Wiley & Sons, New York, 1991.
Nitrogen protecting groups are well known in the art, including (C,Ce) alkoxy carbonyl, optionally substituted benzyloxycarbonyl, aryloxycarbonyl, trityl, vinyloxycarbonyl, O-nitrophenylsulfonyi, diphenyiphosphinyl, p-toluenesutfonyl, and benzyl. The addition of the nitrogen protecting group may be carried out in a chlorinated hydrocarbon solvent such as methylene chloride or 1,2-dichloroethane, or an ethereal solvent such as glyme, diglyme or THF, in the presence or absence of a tertiary amine base such as triethylamine, diisopropylethylamine or pyridine, preferably triethylamine, at a temperature from about 0°C to about 50°C, preferably about ambient temperature. Alternatively, the protecting groups are conveniently attached using Schotten-Baumann conditions.
Subsequent to the above described amine coupling reaction the protecting group may be removed by deprotecting methods known to those skilled in the art such
AP/P/ 96/00805
AP 00637
-17as trifluoroacetic acid in methylene chloride for the tert-butoxvcarbonyl protected products.
Compounds of the Formula I wherein R3 is hydroxy, may preferably be prepared by cleavage of a Formula I compound wherein R3 is (C,-C4)alkoxy.
The cleavage reaction may conveniently be carried out by any of the many procedures known for such a transformation. Treatment of the heteroaryl-fused pyrimidine derivative of Formula I with molten pyridine hydrochloride (20-30 eq.) at 150 to 175°C may be employed for O-dealkylations. Alternatively, the reaction may be carried out, for example, by treatment of the heteroaryl-fused pyrimidine derivative with an alkali metal (C^CJalkylsulphide such as sodium ethanethiolate or, for example, by treatment with an alkali metal diaryiphosphide such as lithium diphenyiphosphide.
Alternatively the cleavage reaction may conveniently be carried out, for example, by treatment of the heteroaryl-fused pyrimidine derivative with a boron or aluminum ( trihalide such as boron tribromide. Such reactions are preferably carried out in the <
presence of a reaction-inert solvent and at a suitable temperature. ' <
For the production of those compounds of Formula I wherein R3 is a (C,CJaJkylsuIphinyl or (C,-C4)alkylsulphony group, the oxidation of a Formula I compound c wherein R3 is a (C,-C4)alkytthio group is preferred. *
A suitable oxidizing agent is, for example, an agent known in the art for the ( *
oxidation of thio to sulphinyl and/or sulphonyl, for example, hydrogen peroxide, a C peracid (such as 3-chloroperoxybenzoic or peroxyacetic acid), an alkali metal * peroxysulphate (such as potassium peroxymonosulphate), chromium trioxide or gaseous oxygen in the presence of platinum. The oxidation is generally carried out under as mild conditions as possible and with the required stoichiometric amount of oxidizing agent in order to reduce the risk of over oxidation and damage to other functional groups. In general the reaction is carried out in a suitable solvent such as methylene chloride, chloroform, acetone, tetrahydrofuran or tert-butvl methyl ether and at a temperature, for example, -25 to 50° C, conveniently at or near ambient temperature, that is in the range of 15 to 35°C. When a compound carrying a sulphinyl group is required a milder oxidizing agent may also be used, for example sodium or potassium metaperiodate, conveniently in a polar solvent such as acetic acid or ethanol. It will be appreciated that when a compound of the Formula I containing a (C, CJalkylsulphonyl group is required, it may be obtained by oxidation of the
AP ο Ο 6 3 7
-18corresponding (C^CJalkylsulphinyl compound as well as of the corresponding (C,CJalkylthio compound.
For the production of those compounds of Formula I wherein R3 is (C2CJalkanoylamino or substituted (C2-C4)alkanoylamino, ureido, 3-phenylureido, benzamido, or sulfonamido, the acylation or sulfonylation of a Formula I compound wherein R3 is amino is appropriate.
A suitable acylating agent is, for example, any agent known in the art for the acylation of amino to acylamino, for example an acyl halide (e.g., a (C2-C4)alkanoyl chloride or bromide or a benzoyl chloride or bromide), an alkanoic acid anhydride or mixed anhydride (e.g., (C2-C4)alkanoic acid anhydride such as acetic anhydride or the mixed anhydride formed by the reaction of an alkanoic acid and a (C,C4)alkoxycarbonyl halide, for example (C,-C4)alkoxycarbonyl chloride, in the presence of a suitable base). For the production of those compounds of Formula I wherein R1 is ureido or 3-phenylureido, a suitable acylating agent is, for example, a cyanate, for example an alkali metal cyanate such as sodium cyanate or, for example, an isocyanate such as phenyl isocyanate. N-sulfonylations may be carried out with suitable sulfonyl halides or suifonylanhydrides in the presence of a tertiary amine base. In general the acylation or sulfonylation is carried out in a reaction-inert solvent and at a temperature, in the range, for example, -30 to 120°C, conveniently at or near ambient temperature.
Forthe production of those compounds of Formula I wherein R3 is (C,-C4)alkoxy or substituted (C,-C4)alkoxy or R1 is (C,-C4)alkylamino or substituted mono-N- or diN,N-(C,-C4)alkylamino, the alkylation, preferably in the presence of a suitable base, of a Formula I compound wherein R1 is hydroxy or amino, as appropriate, is preferred.
A suitable alkylating agent is, for example, any agent known in the art for the alkylation of hydroxy to alkoxy or substituted alkoxy, or for the alkylation of amino to alkylamino or substituted alkylamino, for example an alkyl or substituted alkyl halide, for example a (C,-C4)alkyl chloride, bromide or iodide or a substituted (C,-C4)alkyl chloride, bromide or iodide, in the presence of a suitable base in a reaction-inert solvent and at a temperature in the range, for example, 10 to 140°C, conveniently at or near ambient temperature.
For the production of those compounds of Formula l wherein R3 is an amino-, oxy- or cyano-substituted (C,-C4)aikyl substituent, the reaction, preferably in the presence of a suitable base, of a Formula I compound wherein R3 is a (C,-C4)alkyl
AP/P/ 96/00805
AP 00637
-19substituent bearing a displaceable group with an appropriate amine, alcohol or cyanide is appropriate.
The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range, for example, 10 to 100°C, conveniently at or near ambient temperature.
For the production of those compounds of Formula I wherein R3, R5, or R® is a carboxy substituent or a substituent which includes a carboxy group, the hydrolysis of a Formula I compound wherein R3, R5, R® is a (C,-C4)alkoxycarbonyl substituent or a substituent which includes a (CrC4)aikoxycarbonyl group is desirable.
The hydrolysis may conveniently be performed, for example, under basic conditions such as an alkali meta] hydroxide mediated hydrolysis as illustrated in the accompanying Examples.
For the production of those compounds of Formula I wherein R3 is amino, (C,CJalkylamino.di-KC^CJalkyllamino.pyrrolidin-l-yl.piperidino.morpholino.piperazin-l15 yl, A-fC^CJaikylpiperazin-l-yl or (C^CJalkythio, the reaction, conveniently in the presence of a suitable base, of a Formula I compound wherein R3 is a displaceable group with an appropriate amine or thiol is preferred.
The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range, for example, 10 to 180°C, conveniently in the range 100 to 150°C.
For the production of those compounds of Formula I wherein R3 is 2oxopyrrolidin-1-yi or 2-oxopiperidin-1-yi, the cyclisation, in the presence of a suitable base, of a Formula I compound wherein R3 is a halo-(C2-C4)alkanoylamino group is convenient.
The reaction is preferably carried out in a reaction-inert solvent or diluent and at a temperature in the range, for example, 10 to 100°C, conveniently at or near ambient temperature.
For the production of compounds of Formula I in which R3 is carbamoyl, substituted carbamoyl, alkanoyloxy or substituted alkanoyloxy, the carbamoylation or acylation of a Formula I compound wherein R3 is hydroxy is convenient.
Suitable acylating agents are for example any agent known in the art for acylation of hydroxyaryl moieties to alkanoyloxy aryl. For example, (C2-C4)alkanoyl halides, (C2-C4)alkanoyl anhydrides or mixed anhydrides, and suitable substituted
AP/P/ 9 6 / 0 0 8 0 5
AP 00637
-20derivatives thereof may be employed typically in the presence of a suitable base. Alternatively, (C2-C4)alkanoic acids or suitably substituted derivatives thereof may be coupled with a Formula I compound wherein R3 is hydroxy with the aid of a condensing agent such as a carbodiimide. For the production of those compounds of Formula I in which R3 is carbamoyl or substituted carbamoyl, suitable carbamoyiating agents are for example a cyanate or an alkyl or arylisocyanate, typically in the presence of a suitable base. Alternatively a suitable intermediate such as the chloroformates or imidazolyiacarbonyl derivative of a heteroaryl-fused pyrimidine of Formula I in which R3 is hydroxy may be generated, for example by treatment of said derivative with phosgene (or a phosgene equivalent) or carbonyldiimidazole. The resulting intermediate may then be reacted with an appropriate amine or substituted amine to produce the desired carbamoyl derivatives.
For the production of heteroaryl-fused pyrimidine derivatives of Formula I wherein R3 is aminocarbonyl or a substituted aminocarbonyl, the aminolysis of a suitable intermediate derived from a heteroaryl-fused pyrimidine of Formula I in which R3 is carboxy is preferred.
The activation and coupling of a Formula I compound wherein R3 is carboxy may be performed by a variety of methods known to those skilled in the art. Suitable methods include activation of the carboxyl as an acid halide, azide, symmetric or mixed anhydride, or active ester of appropriate reactivity for coupling with the desired amine. Examples of such types of intermediates and their production and use in couplings with amines may be found extensively in the literature; for example M. Bodansky and A. Bodansky, The Practice of Peptide Synthesis, Springer,-Veriag, New York, 1984.
The resulting Formula I compounds may be isolated and purified by standard methods, such as solvent removal and recrystaliization or chromatography, if desired.
Optionally substituted indole and indolines, useful in the practice of the invention, and methods for their preparation, are described in co-pending United States application serial number 08/200,359, incorporated herein by reference. In addition to methods described therein the preparation of various indolines, indoles, oxindoles, and isatins useful as intermediates are further described in Heterocyclic Compounds with Indole and Carbazole Systems’, W. C. Sumpter and F. M. Miller, in Vol. 8 of The Chemistry of Heterocyclic Compounds Series, Interscience Publishers Inc., N.Y., 1954 and references contained therein.
AP 00637
-21Substituted anilines, useful in the practice of the invention, and methods for their preparation, are described in co-pending United States application 08/413,300 and PCT application no. PCT/IB95/00436, incorporated herein by reference.
Compounds of the formula ZH wherein ZH is QNH2, useful in the practice of the invention, and methods for their preparation, are described in European Patent application serial no. EP 0 496 617 A1 incorporated herein by reference.
Certain compounds of Formula I can exist in solvated as welt as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses ail such solvated as well as unsolvated forms which possess activity against hyperproliferative diseases.
A suitable pharmaceutically-acceptable salt of a heteroaryl-fused pyrimidine derivative of the invention is, for example, an acid-addition salt of a heteroaryl-fused pyrimidine derivative of the invention which is sufficiently basic, for example an acidaddition salt with, for example, an inorganic or organic acid, for example, hydrochloric, hydrobromic, sulphuric, phosphoric, methanesulfonic, benzenesulfonic, trifluoroacetic, citric, lactic or maleic acid, in addition a suitable pharmaceutically-acceptable baseaddition salt of a heteroaryl-fused pyrimidine derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a lithium, sodium or potassium salt; an alkaline earth metal salt, for example a calcium or magnesium salt; an ammonium salt; or a salt with an organic base which affords a physiologically-acceptable cation for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine. All such salts are within the scope of this invention and they can be prepared by conventional methods. For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non-aqueous or partially aqueous medium, as appropriate. The salts are recovered either by filtration, by precipitation with a non-solvent, preferably an ethereal or hydrocarbon solvent, followed by filtration, by evaporation of the solvent, or, in the case of aqueous solutions, by lyophilization, as appropriate.
Some of the compounds of Formula I have asymmetric carbon atoms. Such diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known per se.. for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an
AP/P/ 96/00805
AP 00637
-22appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomer. All such isomers, including diastereomers and enantiomers are considered as part of the invention.
The compounds of this invention are potent inhibitors of the erbB family of oncogenic and protooncogenic protein tyrosine kinases such as epidermal growth factor receptor (EGFR), erbB2. HER3. or HER4 and thus are ail adapted to therapeutic use as antiproliferative agents (e.g., anticancer) in mammals, particularly humans. In particular, the compounds of this invention are therapeutants or prophylactics for the treatment of a variety of human tumors (renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, various head and neck tumors), and other hyperplastic <
conditions such as benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., (
BPH). it is in addition expected that a heteroaryl-fused pyrimidine of the present <
invention may possess activity against a range of leukemias and lymphoid malignancies. c
The compounds of Formula I may also be expected to be useful in the treatment 4 of additional disorders in which aberrant expression ligand/receptor interactions, £ activation or signalling events related to various protein tyrosine kinases, (e.g.. IGF- £ receptors) whose activity is inhibited by the agents of Formula I, are involved. *
Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic nature in which aberrant function, expression, activation or signalling of the tyrosine kinases may be involved, in addition, compounds of Formula I may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases which are inhibited by compounds of Formula I.
The in vitro activity of these compounds in inhibiting the receptor tyrosine kinase (and thus subsequent proliferative response, e.g., cancer) may be determined by a procedure as detailed below. Activity of compunds of Formula I in vitro can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., Lys3 - Gastrin or polyGluTyr (4:1) random copolymer (I. Posner et. al.,
J. Biol. Chem. 267 (29), 20638-47 (1992)) on tyrosine by epidermal growth factor receptor kinase by a test compound relative to a control. Affinity purified, soluble
AP 00637
-23human EGF receptor (96 ng) is obtained according to the procedure in G. N. Gill, W. Weber, Methods in Enzvmoloqy 146. 82-88 (1987) from A431 cells (American Type Culture Collection, Rockville, MD) and preincubated in a microfuge tube with EGF (2pg/ml) in phosphorylation buffer + vanadate (PBV: 50 mM HEPES, pH 7.4; 125 mM
NaCl; 24 mM MgCly, 100 pM sodium orthovanadate), in a total volume of 10 pi, for 2030 minutes at room temperature. The test compound, dissolved in dimethylsulfoxide (DMSO), is diluted in PBV*, and 10 pi is mixed with the EGF receptor /EGF mix, and incubated for 10-30 minutes at 30° C. The phosphorylation reaction is initiated by addition of 20 pi 33P-ATP/ substrate mix (120 pM Lys3-Gastrin (sequence in single letter code for amino acids, KKKGPWLEEEEEAYGWLDF), 50 mM Hepes pH 7.4,40 pM ATP, 2 pCi y-[33P]-ATP) to the EGFr/EGF mix and incubated for 20 minutes at room temperature. The reaction is stopped by addition of 10 pi stop solution (0.5 M EDTA, pH 8; 2mM ATP) and 6pi 2N HCI. The tubes are centrifuged at 14,000 RPM, 4°C, for 10 minutes. 35 pi of supernatant from each tube is pipetted onto a 2.5 cm circle of
Whatman P81 paper, bulk washed four times in 5% acetic acid, 1 liter per wash, and then air dried. This results in the binding of substrate to the paper with loss of free ATP on washing. The [33P] incorporated is measured by liquid scintillation counting. Incorporation in the absence of substrate (e.g., Iys3-gastrin) is subtracted from all values as a background and percent inhibition is calculated relative to controls without test compound present.
Such assays carried out with a range of doses of test compounds allow the determination of an approximate IC60 value for the in vitro inhibition of EGFR kinase activity. Although the inhibitory properties of the compounds of Formula I vary with structural change as expected, in general, the activity exhibited by these agents determined in the manner described above is in the range of IC6O=0.0001-30 pM.
Activity of compounds of Formula I in vivo can be determined by the amount of inhibition of tumor growth by a test compound relative to a control. The tumor growth inhibitory effects of various compounds are measured according to the methods of Corbett T. H., et ai. Tumor Induction Relationships in Development of Transplantable
Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen
Structure, Cancer Res.. 35, 2434-2439 (1975) and Corbett, T. H., et al., A Mouse
Colon-tumor Model for Experimental Therapy, Cancer Chemother, Rep, (Part 2Γ. 5,
169-186 (1975), with slight modifications. Tumors are induced in the left flank by s.c.
AP/P/ 9 6 / 0 0 80 5
AP 00637
-24injection of 1 X 10° log phase cultured tumor cells (human MDA-MB-468 breast or human HN5 head and neck carcinoma cells) suspended in 0.10 ml RPMI 1640. After sufficient time has elapsed for the tumors to become palpable (2-3 mm in diameter) the test animals (athymic mice) are treated with compound (formulated by dissolution in 5 DMSO typically at a concentration of 50 to 100 mg/mL followed by 1:9 dilution into 0.1% Pluronic* P105 in 0.9% saline) by the intraperitoneal (ip) or oral (po) routes of administration twice daily (i.e., every 12 hours) for 5 to 20 consecutive days. In order to determine an anti-tumor effect, the tumor is measured in millimeters with Vernier calipers across two diameters and the tumor size (mg) is calculated using the formula:
Tumor weight = (length x [width]2)/2, according to the methods of Geran, R.I., et al. Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems, Third Edition, Cancer Chemother. Results are expressed u as percent inhibition, according to the formula: Inhibition (%) = (TuWeontrol - <
TuWj.J/TuW^o, x 100%. The flank site of tumor implantation provides reproducible 15 dose/response effects for a variety of chemotherapeutic agents, and the method of measurement (tumor diameter) is a reliable method for assessing tumor growth rates.
Administration of the compounds of this invention can be via any method which enables delivery of the compounds to the site of action (e.g., cancer cells). These methods include oral routes, intraduodenai routes, parenteral injection (including 20 intravenous, subcutaneous, intramuscular, intravascular or infusion), topical administration, etc.
The amount of heteroaryl-fused pyrimidine derivative administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgement of the prescribing physician. However an effective dosage is in the range of approximately 0.1-100 mg/kg, preferably 1 to 35 mg/kg in single or divided doses. For an average 70kg human, this would amount to 0.05 to 7 g/day, preferably 0.2 to 2.5 g/day.
The composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical compositions will include a
A Π/O? a c
AP 00637
-25conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
Pharmaceutical compositions according to the invention may contain 0.1 %-95% 5 of the compound, preferably 1%-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound according to the invention in an amount effective to alleviate or reduce the signs in the subject being treated, i.e., proliferative diseases, over the course of the treatment.
Exemplary parenteral administration forms include solutions or suspensions of 10 a compound according to the invention Formula I in sterile aqueous solutions, for example aqueous propylene glycol or dextrose solutions are employed. Such dosage forms can be suitably buffered, if desired.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid can be employed, together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials therefore
T include lactose or milk sugar and high molecular weight polyethylene glycols. When the aqueous suspensions or elixirs are desired for oral administration the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent, to those skilled in this art.
For examples, see Remington's Pharmaceutical Sciences., Mack Publishing Company,
Easter, Pa., 15th Edition (1975).
The anticancer treatment described above may be applied as a sole therapy or may involve, in addition to the heteroaryl-fused pyrimidine derivative of the invention,
AP/P/ 9 6 / 0 0 8 0 5
AP 00637
-26one or more other antitumor substances. Such conjoint treatment may be achieved by way of the simultaneous, sequential, cyclic or separate dosing of the individual components of the treatment.
It should be understood that the invention is not limited to the particular embodiments shown and described herein, but that various changes and modifications may be made without departing from the spirit and scope of this novel concept as defined by the following claims.
Example 1 (3-Ethvnvl-phenvD-(7H-pvrroloT2.3-dlpvrimldin-4-vD-amlne hydrochloride;
To 4-chloro-7H-pyrrolo [2,3-d] pyrimidine (10.0 g, 0.065 mol) in dry pyridine (90 ml) was added m-aminophenylacetylene (9.2 g, 0.078 mol), and the mixture was heated in an 85°C oil bath for 2 days. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (375 g, 40pm mesh) using 5% methanol/CH2CI2 to afford the title compound as a pink-orange solid (1.9 g, 12% ). HRMS: Calcd. 235.0984, Found 235.1000; anal. RP18-HPLC RT: 3.48 min.
The above compound was dissolved in a minimal amount of methanol and a solution of HCI in ethyl ether (HCI bubbled into 2 ml ethyl ether) was added dropwise until the mixture remained cloudy. The precipitated HCI salt was dried in vacuo, washed once with ethyl ether, and dried in vacuo to constant mass. MP: 196-198°C.
Example 2 (3-Chloro-phenvl)-P,H-pvrrolof2.3-d1pyrimidin-4-vl)-amine
Following the procedure described in Example 1, the title compound was prepared from 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 3-chloroaniline (3.4%). LC-MS: 245 (MH+); anal. RP18-HPLC RT: 3.74 min; HCI salt MP: 227-228°C.
Example 3
4-(6-Chloro-2.3-dihvdro-indol-1-vl)7H-pvrrolo[2.3-d1pyrimldine hydrochloride;
Following the procedure described in Example 1, the title compound was prepared from 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 6-chloro-2,3-dihydroindol-1-yl (4.3%). HRMS: Calcd. 271.0750, Found 271.0729; anal. RP18-HPLC RT: 4.88 min; HCI salt MP: 266°C (dec).
AP 00637
-27Example 4 (7H-Pvrrolor2.3-cnpvrlmldin-4-vlK-rn-tolvl-)amine hydrochloride;
Following the procedure described in Example 1, the title compound was prepared from 4-chloro-7H-pyrroloI2,3-d]pyrimidine and m-toluidine (34%). HRMS:
Calcd. 225.1140, Found 225.1131; anal. RP18-HPLC RT: 3.45 min; HCI salt MP: 219°C.
Example 5 nH-lndol-5-vD-(7H-pvrrolor2.3-d1pvrlmldin-4-vn-aminc hydrochloride:
Following the procedure described in Example 1, the title compound was prepared from 4-chloro-7H-pyrrolo[2,3-d] pyrimidine and 5-aminoindole (7%). HRMS:
Calcd. 250.1093, Found 250.1081; anal. RP18-HPLC RT: 2.58 min; HCI salt MP: 218221 °C.
Example S (Phenyl)-f7H-pvrrolor2.3-cnpvrimldin-4-vl)-amine Utilizing a procedure analogous to that described in Example 1, this product was prepared in 16% yield from 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (1.0 eq) and aniline (5.0 eq) in pyridine. (M.P. 234-236°C; GC-MS: 211 (MH+); anal. RP18-HPLC RT: 3.11 min.)
The compounds of Examples 7-10 were made according to the method of Example 1 from the appropriate starting materials.
AP/P/ 9 6 / 0 0 8 0 5
AP 00637
Ex. Z Yield {%} HPLC El LC/MS M+
7 23 4.62 251
8 57 3.70 267
9 XXy 23 4.66 289
10 H 71 2.23 251
AP 00637
-29Example 11
1-(4-Γγπ-Τolvlamlno1-1-fpvrrolof2.3<npvrimldln-7-vl)-ethanone hydrochloride;
To (3-methyl-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yI)-amine (Example 4) (0.168 g, 0.75 mmol), dissolved in hot acetonitrile (7 ml), was added sodium hydride (36 mg, 0.90 mmol, 60% dispersion in mineral oil). After stirring at ambient temperature for 0.75 hours, acetyl chloride (0.11 ml, 1.5 mmol) was added.and stirring was continued for 48 hours. The mixture was concentrated in vacuo, triturated in hot ethyl acetate and filtered. The filtrate was concentrated in vacuo to give an orange solid residue. The solid was triturated in CH2CI2 and filtered to afford the title compound as a light yellow solid (0.11 g, 55%). LC-MS: 267 (MH+); anal. RP18-HPLC RT: 3.53 min.
Example 12 (5-lodo-7H-pvrroloT2.3-dlpvrimldin-4-vl)-(m-tolvD-amine
To 1-(4-tolylamino-pyrroIo[2,3-d]pyrimidin-7-yl)-ethanone (113 mg, 0.42 mmol), in dry methanol (4 ml), and CH2CI2 (1 ml), was added Na2CO3 (45 mg, 0.42 mmol). After stirring at ambient temperature for 0.75 hours, N-iodosuccinimide (190 mg, 0.85 mmol) was added and stirring was continued for 48 hours. The mixture was concentrated in vacuo and partitioned between CH2CI2 and H2O. The organic phase was washed twice with H2O, dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (7 g, 40 μτη mesh) using 2% methanol/CH2Cl2 to afford the title compound as olive needles (6mg, 4%). LC-MS: 351 (MH*); anal. RP18-HPLC RT: min.
Example 13 (3-Chloro-phenvD-(1 H-F1.2.31triazolof4.5-d1Pvrimidln-7-vl)-amine hydrochloride
To 3-chloroaniiine (0.39 ml, 3.6 mmol) in dry dimethylcyclohexylamine (0.55 ml,
3.6 mmol) was added phosphorus pentoxide (0.52 g, 3.6 mmol). After heating in a 170°C oil bath for 0.5 hours, 8-azahypoxanthine (0.50 g, 3.6 mmol) was added and stirring continued at 170°C for 23 hours. The mixture was cooled to ambient temperature and 2M NaOH was added until basic. The solids were filtered off and washed consecutively with H2O, CH2CI2 and methanol. The resulting solid was dried in vacuo to afford the title compound as a tan powder (0.26 g, 29%). LC-MS: 247 (MH+); anal. RP18-HPLC RT: 3.76 min.
AP/P/ 9 6 / 0 0 B 0 5
AP 00637
-30Example 14 (3-Chloro-phenvh-(pyrldor4.3-cnpvrlmidln-4-vl)-amine hydrochloride;
To 4-hydroxy-pyrido[4,3-d]pyrimidine (0.13 g, 0.90 mmol) in phosphorus oxychloride (2 ml) was added dry pyridine (0.15 ml, 1.8 mmol). A condenser and CaCI2 drying tube were attached and the suspension was refluxed for 3 hours. The final, clear solution was concentrated in vacuo (CaCI2 drying tube) and followed by a toluene chase. The resulting 4-chloro-pyrido[4,3-d]pyrimldine was dissolved in dry pyridine (1.5 ml). 3-Chloroaniline (0.096 ml, 0.90 mmol) was added, and the mixture was heated in an 85°C oil bath for 23 hours. The reaction was cooled to ambient temperature and concentrated in vacuo. The oily residue was partitioned between CH2CI2 and H2O, filtered, and the H2O phase extracted with CH2CI2. The combined organic phases were dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by i flash chromatography on silica gel (5 g, 40 pm mesh) using 5% methanol/CH2CI2 to * afford the title compound as an off-white solid (3 mg, 1.3%). LC-MS: 257 (MH+); anal. t
RP18-HPLC RT: 3.85 min. <
Example 15
I (1 H-lndol-5-vl)-(pvrldoi4.3-d]pvrimldin-4-vl)-amlne hydrochloride; ,
To a suspension of 4-hydroxy-pyrido[4,3-d]pyrimidine (0.103 g, 0.70 mmol) in j dry pyridine (2 ml) cooled in an ice-water bath was added dropwise trifluoroacetic j anhydride (0.20 ml, 1.4 mmol). After stirring for 0.5 hours, a solution of 5-aminoindole , (0.204 g, 1.5 mmol) in dry dimethytformamide (DMF) (1.5 ml) was added dropwise. The cold bath was allowed to warm to ambient temperature and stirring continued for 24 hours. The mixture was concentrated in vacuo and partitioned between CH2CI2 and H2O. The H2O phase was extracted with CH2CI2, and the combined organic phases washed with H2O, dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (11 g, 40 pm mesh) using 5% methanol/CH2CI2 to afford the title compound as an orange solid (37 mg, 20%). LCMS: 262 (MH+); anal. RP18-HPLC RT: 2.02 min.
Example 16 (3-Ethvnvlphenvn-(7-methvl-pvrldoi4.3-d1pyrimidin-4-vn-amlne hydrochloride;
Utilizing a procedure analogous to that described in Example 15, this product was prepared in 28% yield from 4-hydroxy-7-methyl-pyrido[4,3-d]pyrimidine (1.0 eq) and
AP 00637
-31m-aminophenyl acetylene (40.0 eq) in pyridine. The HCI salt was prepared from the purified free base according to the procedure given in Example 1. (M.P. 240-241 °C; GC-MS: 261 (MH+); anal. RP18-HPLC RT: 3.73 min.)
Example 17 (3-Chloro-phenvl)-(7-methvl-pvridof4.3-d1pyrimldin-4-vl)-amine hydrochloride;
Utilizing a procedure analogous to that described in Example 16, this product was prepared in 34 % yield from 4-hydroxy-7-methyl-pyrido[4,3-d]pyrimidine (1.0 eq) and m-chloroaniline (40.0 eq) in pyridine. The HCI salt was generated from the purified free base according to the procedure given in Example 1. (M.P. 255-256°C; GC-MS:
270 (MH*); anal. RP18-HPLC RT: 4.05 min.)
Example 18 (3-Ethvnvl-phenvD-foyridor4.3-d1pvrlmldln-4-vD-amine hydrochloride;
Following the procedure described in Example 16, the title compound was prepared from 4-hydroxy-pyrido[4,3-d]pyrimidine and m-aminophenyl acetylene (5%).
LC-MS: 247 (MH*); anal. RP18-HPLC RT; 3.41 min.
The compounds of Examples 19-24 were made according to the method of Example 15 from the appropriate starting materials.
AP/P/ 96/06805
AP 00637
Ex. Z Yield 1%) HPLC BI LC/MS M±
19 Xy 45 3.64 359
20 315
21 H 277
22 h°-^3^nh^ 267
23 i'^Q/ 389
24 <oonh^ 55 3.44 341
if
C a
c c
tx c
fl ** fl <
AP 00637
-33Example 25 (3-Ethvnvl-phenylM9H-purin-6-vD-amlne To 6-chloropurine (1.0 g, 6.5 mmol) in dry pyridine (10 ml) was added maminophenyt acetylene (0.91 g, 7.8 mmol). The mixture was heated in an 85°C oil bath for 23 hours. The mixture was cooled to ambient temperature and concentrated in vacuo. The oily residue was partitioned between CH2CI2 and H2O then filtered to afford the title compound as a light orange solid (50 mg, 3.3%). LC-MS: 236 (MH*); anal. RP18-HPLC RT: 3.25 min.
Example 26 (1 H-lndol-5-vl)-(9H-purln-6-vD-amlne hydrochloride
Following the procedure described in Example 9, the title compound was prepared from 6-chloropurine and 5-aminoindole (70%). TS-MS: 251 (MH+); anal. RP18-HPLC RT: 2.44 min.
Example 27 (3-Chloro-phenv0-(9H-purln-6-vB-amine hydrochloride
Following the procedure described in Example 1, the title compound was prepared from 4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 3-chloroaniline (3.4%). LC-MS: 245 (MH+); anal. RP18-HPLC RT: 3.74 min; HCI salt MP: 227-228°C.
Example 28
4-(6-Chloro-2.3-dihvdro-indol-1-vl)-pvrido[3.4-dTpyrimidine
4-Chloropyrido [3,4-d] pyrimidine (0.1 Og, 0.60 mmol), 6-chloroindoline (0.1 Og,
0.66 mmol) and pyridine (0.14g, 1.81 mmol) were combined in DMF (1 mL) and heated at 70°C for 3 hr. The reaction was cooled to room temperature and then added to methylene chloride (150 mL). The organic layer was washed with saturated sodium carbonate and water and then dried over sodium sulfate. The solvent was removed by rotary evaporation and the residue purified by column chromatography (silica gel, 9/2/1 - CHjCIj/hexanes/methanol) to give a pale yellow residue (0.048g, 28%). MP 194-6°C; LCMS: 283 (MH+).
The products of examples 29-31 were prepared according to the method of
Example 1 from 4-chloropyrido[3,4-d]pyrimidine (1 eq.) and the indicated amine.
$0800/96 /d/dV
AP 00637
-34Example 29 (Pvridor3.4-dtpvrimldin-4-vlH-m-tolvB-amine This product was prepared in 44% yield from m-anisidine (1.1 eq.) MP 172°C;
LC-MS: 237 (MH+).
Example 30 (1 H-lndazol-5-vlK-pvridoF3.4-d1pvrlmldln-4-vB-amlne
This product was prepared in 96% yield from 5-aminoindazole (1.1 eq.) MP 258°C; LC-MS: 263 (MH+).
Example 31 (1H-lndol-5-vlK-Pvrldoi3.4-dlpvrlmidln-4-vl-)amine
This product was prepared in 15% yield from 5-aminoindole (1.1 eq.) 4chloropyrido[3,4-d]pyrimidine (1 eq.) MP 265°C; LC-MS: 262 (MH+).
Example 32 (PhenvlH-pvrldor2.3-d1pyrlmidln-4-vl-)amine
4-Chloropyrido [2,3-d]pyrimidine (0.15g, 0.91 mmol) was carefully added to a solution of aniline (0.15g, 1.61 mmol) in water (1.5 mL). The solution was heated for 0.5 hour on a steam bath, cooled, and then basified with cone, ammonium hydroxide. The crude precipitate was collected by filtration and recrystallized from 95% ethanol to give the title product as yellow crystals (0.054g, 27%). MP 258°C; LC-MS: 223 (MH+).
The products of Examples 33-36 were prepared according to the procedure of
Example 5 from 4-chloropyrido[2,3-d]pyrimidine (1 eq.) and the appropriate substituted aniline.
Example 33 (3-Chloro-phenvD(-pyrldor2.3-dlpvrlmidin-4-vl-)aminc
This product was prepared in 61% yield from m-chloroaniline (1.8 eq.).
MP 228°C; LC-MS: 257 (MH+).
Example 34 (3-Chloro-phenvlK-pyridor3.4-dlpyrimidin-4-vl-)amine This product was prepared in 37% yield from m-chloroaniline (1.8 eq.). MP
228°C; LC-MS: 257 (MH+).
λοιοι ο fi / n 0 8 0 5
AP 00637
-35Example 35 (3-Bromo-phenvl)(-pvridor3.4-d1pvrlmldin-4-yl-)amine
This product was prepared in 26% yield from m-bromoanlline (1.8 eq.). MP
206°C; LC-MS: 301 (MH+).
Example 36 (Phenyl) (-pyrido [3,4-dl pyrimldin-4-yl-)amine
This product was prepared in 22% yield from aniline (1.8 eq.). MP 161 °C; LCMS: 223 (MH+).
Example 37
4-(6-Chloro-2,3-dihvdro-indoI-1-vl)-pvridof3.4-dlpvrimidine
4-Chloropyrido[3,4-d]pyrimidine (0.1 Og, 0.60 mmol), 6-chloroindoline (0.10g,
0.66 mmol) and pyridine (0.14g, 1.81 mmol) were combined in DMF (1 mL) and heated at 70°C for 3 hours. The reaction was cooled to room temperature and then added to methylene chloride (150 mL). The organic layer was washed with saturated sodium carbonate and water and then dried over sodium sulfate. The solvent was removed by rotary evaporation and the residue purified by column chromatography (silica gel, 9/2/1 - CH2CI2/hexanes/methanol) to give the title product as a pale yellow residue (0.048g, 28%). MP 194-6°C; LCMS: 283 (MH+).
Example 38 (Pvridor3.4-d1pyrimidin-4-vD(-m-tolvl-)amine
This product was prepared in 44% yield from m-anisidine (1.1 eq.) MP 172°C;
LC-MS: 237 (MH+).
The products of Examples 39-40 were prepared according to the procedure of Example 1 from 4-chloropyrido[3,4-d]pyrimidine (1 eq.) and the appropriate amine.
Example 39 (1 H-indazol-5-vl)(-pyrldo[3.4-d1Pvrlmidin-4-vl-)amine
This product was prepared in 96% yield from 5-aminoindazole (1.1 eq.) and 4chloropyrido[3,4-d]pyrimidine (1 eq.). MP 258°C; LC-MS: 263 (MH+).
Example 40 (1 H-lndol-5-vl)(-pvrido[3.4-d]pvrimidin-4-vl-)amlne
This product was prepared in 15% yield from 5-aminoindole (1.1 eq.) and 4chloropyrido[3,4-d]pyrimidine (1 eq.). MP 265°C; LC-MS: 262 (MH+).
s 0 8 0 0 / 9 6 /d/dV
AP 00637
-36Example 41 (Phenvl)-pvridor2.3-d1pvrimlclln-4-vl-amine 4-Chloropyrido [2,3-d]pyrimidine (0.15g, 0.91 mmol) was carefully added to a solution of aniline (0.15g, 1.61 mmol) in water (1.5 mL). The solution was heated for
0.5h on a steam bath, cooled, and then basified with cone, ammonium hydroxide. The crude precipitate was collected by filtration and recrystallized from 95% ethanol to give yellow crystals (0.054g, 27%). MP 258°C; LC-MS: 223 (MH+).
Example 42 (3-Chloro-phenvO(-pvridor2.3-d1pyrlmidin-4-vl)-amine
Using a procedure analogous to that described in Example 5, this product was prepared in 61% yield from m-chloroaniline (1.8 eq.) and 4-chloropyrido[2,3d]pyrimidine (1 eq.). MP 228°C; LC-MS: 257 (MH+).
Example 43 u
(3-Chloro-phenvIH-pvridof3.4-cnpvrimidin-4-vl-)amine
Using a procedure analogous to that described in Example 5, this product was ( prepared in 37% yield from m-chloroaniline (1.8 eq.) and 4-chloropyrido[3,4- * djpyrimidine (1 eq.). MP 228°C; LC-MS: 257 (MH+). *
Example 44 <
(3-Bromo-phenvI)f-pyrldoF3.4-dipvrlmidln-4-vl-)amlne '
Using a procedure analogous to that described in Example 5, this product was ) prepared in 26% yield from m-bromoaniline (1.8 eq.) and 4-chloropyrido[3,4d]pyrimidine (1 eq.). MP 206°C; LC-MS: 301 (MH+).
Example 45 (PhenvD(-pvridor3.4-d1pyrim1dln-4-vl-)amlne
Using a procedure analogous to that described in Example 5, this product was prepared in 22% yield from aniline (1.8 eq.) and 4-chloropyrido[3,4-d]pyrimidine (1 eq.).
MP 161 °C; LC-MS: 223 (MH+).
Example 46 f7-Benzenesulfonvl-7H-pvrrolof2.3-d1pvrimidln-4-vl)-(3-ethvnvl-phenvl)-amine
To 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (1.0 g, 0.0065 mol) in dry THF (10 ml) under nitrogen at -78° C was added dropwise via syringe over 15 minutes η-butyll'rthium (2.5 M in hexane; 2.88 ml, 0.0072 mol). The cooling bath was removed and the solution was stirred for 1 hour. The resulting pyrrolo anion salt precipitated as a very
AP 00637
-37fine white solid in a cloudy colorless solution. After the suspension was recooled to 78°C, benzenesulfonyl chloride (1.26 g, 0.0072 mol) was added neat via syringe. The resulting yellow reaction mixture was allowed to warm slowly to room temperature overnight. The grey-white suspension was poured into 2% aqueous sodium bicarbonate (50 mL) and extracted with two times with diethyl ether (20mL). The combined extracts were washed with water and dried (potassium carbonate) and evaporated to give a light amber oil which crystallized from ether, the product was collected by filtration to 1.4 g (74%) of white solid. LC-MS= 294 (MH+) RP18-HPLC RT: 4.40 min.
The above compound was dissolved in methanol and m-aminophenyl acetylene (0.159 g, 0.0013 mol), and the reaction mixture heated in an 85°C oil bath for 2 days. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The residue was titurated with diethyl ether to produce the title product as a white solid (0.234 g, 92%). LC-MS= 375 (MH+), RP18-HPLC RT: 3.48 min.
Example 47
4-fe-Chioro-2.3-dihvdro-indol-1-vi)-5H-pvrrolof3.2-d1pyrimldin-6-ol To a solution of 4-(6-Chloro-2,3-dihydro-indol-1-yl)-5-amino-6-methylacetyl· pyrimidine (541 mg, 1.55 mmol) in 40 mL of ethanol was added 25 mol% of 10% palladium on carbon (125 mg) and 0.11 mL of 1N HCI (1.55 mmol). The reaction mixture was hydrogenated for 3 hours at 50 psi. The reaction mixture was filtered through Celite and concetrated in vacuo. The brown residue was slurried in methanol and the white solid title product was filtered off (279 mg, 63%)LC-MS= 287 (M+), RP18-HPLC RT: 5.61 min. MP: 250°C (dec).
Example 48 (3-Ethvnvl-phenvn-i7-(2-morpholin-4-vi-ethvD-7H-pvrrolor2.3-dfpyrimidin-4-vllamine
To a solution of 184 mg (1.4 mmol) of 4-(2-hydroxyethyl)morpholine in 10 mL of toluene was added 276 mg (2.0 mmol) of anhydrous potasium carbonate and then 32 mg (1.3 mmol) of 97% sodium hydride. After 30 minutes 343 mg (1.0 mmol) of sulfonylated 4-chloro-7H-pyrrolo[2,3-d]pyrimidine was added and the reaction mixture was heated at 100°C for 2 hours. The reaction mixture was then partitioned between ethyl acetate and water and the aqueous layer was extracted with two additional portions of ethyl acetate. The combined organic phases were washed with water, dried
AP/P/ 96 / 0 0 80 5
AP 00637
-38over magnesium sulfate and concentrated in vacuo. The residue was chromatographed on silica gel using 10% methanol/methylene chloride to give an amber oil (140 mg,
55%). LC-MS 267 (M+)
The above product was dissolved in methanol and m-aminophenyl acetylene (0.123 g, 0.001 mol), and the reaction mixture was heated in a sealed tube in a 120°C oil bath for 12 hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The residue was titurated with diethyl ether to produce the title product as a white solid (0.135 g, 74%). LC-MS= 348 (MH+), RP18-HPLC RT: 3.33 min.
Example 49 (3-Ethvnvl-phenvl)-r7-{2-methoxv-ethvl)-7H-pvrrolof2.3-d1pyrimidin-4-vl1-amine
Utilizing a procedure analogous to that described in Example 47, this product u was prepared in 81 % yieldfrom 4-chloro-7-(2-methoxy-ethyl)-7H-pyrrolo [2,3-d]pyrimidine <
(1.0 eq) and m-aminophenyl acetylene (1.2 eq) in methanol. M.P. 240-241 °C; LC-MS: C
292(MH+); RP18-HPLC RT: 4.16 min. c
Example 50 (3-Ethvnvl-phenvl)-f7-i2-(2-methoxv-ethoxv)-ethvH-7H-pyrrolor2.3-cnpvrimidin-4-vl)amine r
Utilizing a procedure analogous to that described in Example 47, this product 5 20 was prepared in 81 % yield from 4-chloro-7-[2-(2-methoxy-ethoxy)-ethyl]-7H-pyrrolo[2,3djpyrimidine (1.0 eq) and m-aminophenyl acetylene (1.2 eq) in methanol. M.P. 240241 °C; LC-MS: 336 (M+); RP18-HPLC RT: 4.29 min.
Example 51 (7-AHvl-pvrrolor2.3-dlPvrlmldln-4-vD-(3-ethvnyl-phenvD-amine hydrochloride 25 To 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (1.3 g, 8.5 mmol) in dry THF (30 ml) was added sodium hydride (1.0 g, 0.25 mmol, 60% dispersion in mineral oil). After stirring at ambient temperature for 1 hour, allyl iodide (0.93 ml, 10 mmol) was added and stirring was continued for 48 hours. The reaction mixture was concentrated in vacuo, triturated in hot ethyl acetate, and filtered. The filtrate was concentrated in vacuo to give an orange solid residue. The solid was triturated in methylene chloride and filtered to afford 4-chloro-7-allyl-pyrrolopyrimidine as a light yellow powder (0.58 g, 36%). TS-MS:
194 (MH+).
AP 00637
-39To 4-chloro-7-allyl-pyrrolo[2,3-d]pyrimidine (0.5 g, 2.6 mmol) in dry methanol (5 ml) was added m-aminophenyl acetylene (0.36 g, 3.1 mmol). The suspension was heated in a sealed pressure tube at 125°C for 20 hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The resulting oil was purified by flash chromatography on silica gel (50 g, 40 mm mesh) using 3% methanol/methylene chloride to afford the title product as a yellow powder (0.29 g, 41% ). Mp 150-150°C; TS-MS: 275 (MH+).
Example 52 (3-Ethvnvl-phenvB-f7-methvl-pvrrolor2.3-dlpyrlmldln-4-vl)-amlne hydrochloride
Following the procedure described in Example 51, the title compound was prepared from 4-chIoro-7H-pyrrolo[2,3-d]pyrimidine and methyl iodide, and maminophenyl acetylene (75%). TS-MS: 249 (MH+); mp 204-205°C.
Example 53 (5-Bromo-7H-pyrrolor2.3-cf|pvrimidin-4-vB-(3-ethvnvl-phenvD-amine
To 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.21 g, 1.4 mmol) in dry methylene chloride (10 ml) was added N-bromosuccinimide (0.26 g, 1.5 mmol) at ambient temperature. The reaction mixture was stirred for 18 hours, and the resulting solid filtered with methylene chloride washes and dried in vacuo to afford 5-bromo-4-chloro7H-pyrrolo[2,3-d]pyrimidine as a tan powder (0.28 g, 88%). GC-MS: 233 (MH+), RT:
4.42 min.
To 5-bromo-4-chioro-7H-pyrrolo[2,3-d]pyrimidine (0.13 g, 0.57 mmol) in dry methanol (2 ml) was added m-aminophenyl acetylene (0.08 g, 0.68 mmol). The suspension was heated in a sealed pressure tube at 125°C for 18 hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The resulting oil was purified by flash chromatography on silica gel (10 g, 40 mm mesh) using 3% methanol/methylene chloride to afford the title compound as a yellow powder (71 mg, 39% ). TS-MS: 314 (MH+); MP 208°C (dec).
Example 54 (3-Ethvnvl-phenv0-(5-lodo-7H-pvrrolor2.3-d1pyrlmidin-4-vl)-amlne
To(3-methyl-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine(17mgI0.076mmol) in dry methylene chloride (1ml) was added N-iodosuccinimide (19 mg, 0.083 mmol).
The reaction mixture was stirred at ambient temperature for 2 hours then filtered with
AP/P/ 96 / 0 0 80 5
AP 00637
-40a methylene chloride wash and dried in vacuo to afford the title compound as a greytan powder (12 mg, 46%). TS-MS: 351 (MH+).
Example 55
4-(3-Ethvnvl-phenvlamIno)-7H-pvrrolof2.3-dlpvrimidine-5-carboxvlic acid
To 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.87 g, 3.7 mmol) in dry THF (29 ml) cooled in a dry ice-acetone bath was added dropwise n-butyllithium (3.4 mi, 8.4 mmol, 2.5 M in hexanes). The reaction mixture was stirred for 1 hour then quenched by bubbling in CO2. To the resulting olive suspension was added water (1 ml) and stirred for 5 minutes at ambient temperature. The reaction mixture was concentrated in vacuo, triturated with ethyl acetate, and dried in vacuo to afford 4-chloro-7H-pyrrolo[2,3d]pyrimidine-5-carboxylic acid as an avocado powder (0.80 g, 74% ). TS-MS: 198 (MH+).
To 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid (0.38 g, 1.9 mmol) in dry methanol (4 ml) was added m-aminophenyl acetylene (0.47 g, 4.0 mmol). The suspension was heated in a sealed pressure tube at 125°C for 18 hours. The reaction mixture was cooled to ambient temperature, filtered with methylene chloride washes and dried in vacuo to afford the title compound as a tan powder (0.30 g, 54% ). TSMS: 278 (MH+) MP 190°C (dec).
Example 56 (3-Ethvnvl-phenvn-f5-methvl-7H-pyrroloi2.3-dlpvrlmidin-4-vl)-amlne hydrochloride
To 5-bromo-4-chloro-7H-pyrrolopyrimidine (0.28 g, 1.2 mmol) in dry THF (9 ml) cooled in a dry ice-acetone bath was added dropwise n-butyllithium (1.1 ml, 2.7 mmol,
2.5 M in hexanes). The reaction mixture was stirred for 1 hour, then methyl iodide (0.12 ml, 1.9 mmol) was added. The solution was stirred for 1 hour at ambient temperature, and water (1 mi) was added. The reaction mixture was concentrated in vacuo, and diluted with ethyl acetate and water. The organic phase was washed twice with water, dried over sodium sulfate , and concentrated in vacuo to afford 4-chloro-5-methyl-7Hpyrrolo[2,3-d]pyrimidine (0.17 g, 85%). GC-MS: 167(M+), RT: 3.15 min.
To 4-chloro-5-methyl-7H-pyrrolopyrimidine (0.17 g, 1.0 mmol) in dry methanol (3 ml) was added m-aminophenyl acetylene (0.14 g, 1.2 mmol). The suspension was heated in a sealed pressure tube at 125°C for 18 hours. The reaction mixture was cooled to ambient temperature, and concentrated in vacuo. The resulting residue was
AD/D/ G A / ft ft Q ft S
ΑΡ Ου 637
-«1purified by flash chromatography on silica gel (15 g, 40 mm mesh) using 5% methanol/methylene chloride to afford the title compound as a yellow solid (0.11 g, 43%). TS-MS: 249 (MH+).
Example 57
N-(5-lodo-7H-pvrroloF2.3-dlpyrlmidln-4-vl)-N-m-tolvl-acetamlde
To (3-methyl-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine (0.75 g, 3.4 mmol) dissolved in hot acetonitrile (30ml) was added sodium hydride (0.16 g, 4.0 mmol, 60% dispersion in mineral oil). After stirring at ambient temperature for 0.75 hours, acetyl chloride (0.48 ml, 6.7 mmol) was added.and stirring continued for 48 hours. The reaction mixture was concentrated in vacuo, triturated in hot ethyl acetate, and filtered. The filtrate was concentrated in vacuo to give an orange solid residue. The solid was purified by flash chromatography on silica gel (13 g, 40 mm mesh) using 1:3 ethyl acetate/hexanes to afford 1-(4-m-tolylamino-pyrrolo[2,3-d]pyrimidin-7-yl)-ethanone as a yellow solid (0.21 g). TS-MS: 309 (MH+).
To 1 -(4-m-tolylamino-pyrrolo[2,3-d]pyrimidin-7-yl)-ethanone (0.21 g, 0.79 mmol) in dry methylene chloride (5 ml) and dry methanol (2 ml) was added sodium carbonate (0.17 g, 1.6 mmol). After stirring at ambient temperature for 0.75 hours, Niodosuccinimde (0.35 g, 1.6 mmol) was added. The reaction mixture was stirred at ambient temperature for 48 hours then concentrated in vacuo. The residue was diluted with methylene chloride and water. The water phase was extracted once with methylene chloride . The organic phase was washed twice with water, dried over sodium sulfate, and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (11 g, 40 mm mesh) using 2% methanol/methylene chloride to afford the title compound as a yellow solid (30 mg ). TS-MS: 393 (MH+)
MP 178-9 °C.
Example 58
4-(3-Ethvnvl-phenvlamino)-7H-pvrrolor2.3-dlpyrlmidlne-5-carboxylic acid methyl ester hydrochloride
To 4-(3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid (0.108 g, 0.39 mmol) in dry methylene chloride (2 ml) was added a solution of oxalyl chloride (0.17 ml, 1.9 mmol) in dry methylene chloride (4 ml) followed by 1 drop of dry DMF. The suspension was stirred at ambient temperature for 1 hour, then concentrated in vacuo. To the resulting solid was added dry acetone (2 ml) and dry methanol (1 ml).
AP/P/ 96/00805
AP 00637
-42The solution was stirred at ambient temperature for 15 hours, then concentrated in vacuo. The residue was diluted with ethyl acetate and water, and the solid filtered and dried in vacuo to afford the title compound as a tan powder (40 mg, 35%). TS-MS: 293 (MH+) MP 256°C (dec).
Example 59 (3-ethvnvl-phenvlamino)-(7H-pyrrolor2.3<npvrlmldin-5-vl-carbonltrile
To 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.31 g, 1.3 mmol) in dry THF (4 ml), cooled in a dry ice-acetone bath, was added dropwise n-butyllithium (1.3 ml, 3.3 mmol, 2.5 M in hexanes). The reaction mixture was stirred for 1 hour, then p10 toluenesulphonyt cyanide (0.44 g, 2.4 mmol) suspended in dry THF (7 ml) was added. The solution was stirred for 18 hours at ambient temperature then diluted with aqueous ammonium chloride. The phases were separated and the organic phase washed with water and aqueous NaCI. The organic phase was dried over sodium sulfate , and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (15 g, 40 mm mesh) using 3% methanol/methylene chloride to afford 4chloro-5-cyano-7H-pyrrolo[2,3-d]pyrimidine as a yellow solid (52 mg).
To 4-chloro-5-cyano-7H-pyrrolo[2,3-d]pyrimidine (52 mg, 0.29 mmol) in dry methanol (3 ml) was added m-aminophenyl acetylene (41 m g, 0.35 mmol). The suspension was heated in a sealed pressure tube at 125°C for 18 hours. The reaction mixture was cooled to ambient temperature, filtered with a small amount of methanol, and dried in vacuo to afford the title compound as a white solid (27mg, 36%). TS-MS: 260 (MH+); anal. RP18-HPLC RT: 3.70 min.
Example 60 (1 H-lndazol-5-vl)-(6-methvl-pvridof3.4-d1pyrlmidin-4-vl)-amine hydrochloride
6-Methyl-pyrido[3,4-d]pyrimid-4-one (200 mg, 1.24 mmol), polymer-supported triphenylphosphine (2.06 g of about 3.0 mmol P/g resin, 6.20 mmol) and anhydrous carbon tetrachloride (1.20 ml_ 12.40 mmol) were combined in 1,2-dichloroethane (6 mL). The reaction mixture was heated to 60°C under an atmosphere of dry nitrogen for 18 hours. 5-Aminoindazole (221 mg, 1.66 mmol) was added and heating was continued at 60°C for another 18 hours. The triphenyphosphine-supporting polymer was filtered off and washed several times with chloroform. The filtrate and washings were concentrated in vacuo, and flash chromatographed on silica in 10% methanol / siubuu/yo ζαζα v
AP 00637
-430.1% triethylamine/ 89.9% methylene chloride to afford 207 mg of the free base of the title product (LC-MS: 277(MH+). This material was dissolved in a minimum volume of chloroform and 1 mole equivalent of HCl in ether was added dropwise with stirring. The reaction mixture was diluted with ether (4 volumes) and the precipitated HCl salt of the title product was filtered and dried in vacuo (188 mg; M.P. 208°C; LC-MS: 277 (MH+); anal. RP-HPLC: 2.71 min.)
Example 61 (3-Ethvnvl-4-fluoro-phenvB-(6-methvl-pvridor3.4-d1pvrlmidin-4-vB-amlne
This material was prepared from 6-methyi-pyrido[3,4-d]pyrimid-4-one (1.0 eq.) and 5-amino-benzo[b]thiophene (1.5 eq.) as described for Example 60. The polymer was filtered off and washed several times with 30% methanol / 70%chloroform. Triethylamine (3.0 eq) was added to the filtrate and washings before they were concentrated in vacuo. The residue was flash chromatographed on silica in 10%methanol / methylenechlorideto afford 135mg of product as the free base (LC-MS:
293(MH+)). This material was dissolved in a minimum volume of chloroform and 1 mole equivalent of HCl in ether was added dropwise with stirring. The reaction mixture was diluted with ether (4 volumes) and the precipitated title product was filtered and dried in vacuo (152 mg; M.P. 273-276°C; LC-MS: 293 (MH+); anal. RP-HPLC: 4.10 min.).
Example 62.
(3-Ethvnvl-4-fluoro-phenvn-(6-methvl-pvridof3.4-dlpvrimidin-4-vl)-amlne
6-Methyl-pyrido[3,4-d]pyrimid-4-one (44mg, 0.27 mmol), polymer -supported triphenytphosphine (0.452 g of about 3.0 mmol P/g resin, 1.55 mmol) and anhydrous carbon tetrachloride (0.261 mL, 2.71 mmol) were combined in 1,2-dichloroethane (1.25 mL). The reaction mixture was heated to 60°C under an atmosphere of dry nitrogen for 2 hours. 3-Ethynyl-4-fluoro-aniline (55 mg, 0.407 mmol) was added and heating was continued at 60°C for 6 hours. The polymer was filtered off and washed several times with 50% methanol / chloroform. The filtrate and washings were concentrated in vacuo and flash chromatographed on silica with gradient from 0 to 10% methanol I methylene chloride to afford the title product (10 mg; M.P. 225°C; LC-MS: 279 (MH+); anal. RPHPLC: 3.94 min.).
AP/P/ 9 6 / 0 0 8 0 5
AP 00637
44Example 63
2-Methvl-4-(e-methvl-pvrldoF3.4-dlpvrimldln-4-vlamlno)-phenol dlhvdrochloride
This material was prepared from 6-methyl-pyrido[3,4-d]pyrimid-4-one (1.0 eq.) and 4-amino-o-cresol (1.5 eq.) as described for Example 61. The triphenyphosphinesupporting polymer was filtered off and washed several times with 50% methanol /chloroform. Triethylamine (3.0 eq) was added to the filtrate before concentrating in vacuo. The residue was flash chromatographed on silica with gradient from 0 to 15% methanol / methylene chloride to afford 314 mg of title product as the free base (LC10 MS: 267(MH+). This material was converted to the dihydrochloride salt by dissolution in CHCI3 and titration with 2 equivalents of 1M HCI in ether. The precipitated title product was filtered and dried in vacuo (M.P. 298-305°C; LC-MS: 267 (MH+); anal. RP-HPLC: 2.88 min.).
Example 64
4-F4-Bromo-7-methvl-2.3-dlhvdro-lndol-1-vl)-e-methyl-pvrldoF3.4-d1pvrlmidine hydrochloride This product was prepared from 6-methyl-pyrido[3I4-d]pyrimid-4-one (1.0 eq.) ς and 4-bromo-7-methyl-indoline (1.5 eq.) according to the procedure described for Example 61. The crude product from the filtrate was flash chromatographed on silica ( using ethyl acetate / hexanes/ methanol (9:2:1) to afford the free base of the title product which was converted to the title product as described for Example 60 (33%;
M.P. 232-244 °C; LC-MS: 355, 357 (MH+); anal. RP-HPLC: 5.20 min.).
Example 65
4-f6-Bromo-7-methvl-2.3-dlhvdro-lndol-1-vl)-6-methvl-pvrldof3.4-d1pyrlmidine hydrochloride
This product was prepared from 6-methyl-pyrido[3,4-d]pyrimid-4-one (1.0 eq.) and 6bromo-7-methyl-indoline (1.5 eq.) according to the procedure described for Example 61. The crude product from the filtrate was flash chromatographed on silica using ethyl acetate / hexanes/ methanol (9:2:1) to afford the free base of the title product which was converted to the title product salt as described for Example 60 (34%; M.P. 212-229 °C; LC-MS: 355, 357 (MH+); anal. RP-HPLC: 4.90 min.).
ft Λ
AP 00637
-45Example 66
4-(6-Bromo-5-fluoro-2.3-dthvdro-lndol-1-vl)-6-methvl-pvridor3.4-cfl pyrimidine hydrochloride
This product was prepared from 6-methyl-pyrido[3,4-d]pyrimid-4-one (1.0 eq.) 5 and 6-bromo-5-fluoro-indoline (1.5 eq.) according to the procedure described for Example 61. The crude product from the filtrate was flash chromatographed on silica using 2% methanol / 98% methylene chloride to afford the free base of the title product which was converted to the title product as described for Example 60 (36%; M.P. 262264 °C; LC-MS: 359, 361 (MH+); anal. RP-HPLC: 4.83 min.).
Example 67 (3-Chloro-4-fluoro-phenvl)-(6-methvl-pvrldof3.4-dlpvrimidln-4-vl)-amine hydrochloride
This product was prepared from 6-methy1-pyrido[3,4-d]pyrimid-4-one (1.0 eq.) and 3-chloro-4-fluoro-aniline (1.5 eq.) according to the procedure described for Example
61. The crude product from the filtrate was chromatographed on silica using a gradient of 0% to 10% methanol / methylene chloride to afford the free base of the title product which was converted to the title product as described for Example 60 (47%; M.P. 251258 °C; LC-MS: 289, 291 (MH+); anal. RP-HPLC: 4.18 min.).
Example 68 (6-Methvl-pvrldor3.4-dlpvrlmidln-4-vD-(3-trlfluoromethvl-phenvl)-amine hydrochloride
This product was prepared from 6-methyi-pyrido[3,4-d]pyrimid-4-one (1.0 eq.) and 3-trifluoromethyl-aniline (1.5 eq.) according to the procedure described for Example 61. The crude product from the filtrate was chromatographed on silica using a gradient of 0% to 5% methanol / methylene chloride to afford the free base of the title product which was converted to the title product as described for Example 60 (33%; M.P. 269270 °C; LC-MS: 305 (MH+); anal. RP-HPLC: 4.30 min.).
Example 69 (4-Fluoro-3-methvl-phenvB-(6-methvl-pvridor3.4-d1pyrimidin-4-vh-amlne hydrochloride
This product was prepared from 6-methyl-pyrido(3,4-d]pyrimid-4-one (1.0 eq.) and 4-fiuoro-3-methyl-aniline (1.5 eq.) according to the procedure described for
Example 61. The crude product from the filtrate was chromatographed on silica using
S 0 8 0 0 / 9 6 /d/dV
AP 00637
-464% methanol / 96% methylene chloride to afford the free base of the title product which was converted to the title product as described for Example 60 (41%; M.P. 246250 °C; LC-MS: 269 (MH+); anal. RP-HPLC: 3.79 min.).
Example 70
2-lodo-4-(6-methvl-pvridor3.4-d1pvrimidln-4-vlamino)-phenol hydrochloride
6-Methyl-pyrido[3,4-d]pyrimid-4-one (161 mg, 1.00 mmol) was added to polymersupported triphenylphosphine (1.66 g of about 3 mmol P/g polymer; 5.0 mmol) along with CCI4 (1.54 g, 10.0 mmol) in 1,2-dichloroethane (6 mL). The reaction mixture was heated to 60°C for 2 hours and then the resin was filtered and washed with 1,210 dichloroethane. The filtrate was collected in a flask containing 4-hydroxy-3-iodo-aniline (0.235 g, 1.00 mmol) and concentrated to 5 mL by evaporation. After 12 hours reflux under nitrogen followed by cooling to 20°C, the title product was collected by filtration (347 mg; 83%; M.P. 261-265 °C; LC-MS: 379 (MH+); anal. RP-HPLC: 3.20 min.).
Example 71 (4-Bromo-3-fluoro-phenvl)-(6-methvl-pvridor3.4-d1pyrlmidin-4-vl)-amlne hydrochloride
This product was prepared from 6-methyl-pyrido[3,4-d]pyrimid-4-one (1 eq.) and
3- bromo-4-fluoro-aniline (1.0 eq.) and isolated according to the method employed for Example 70 (53%; M.P. 251-254 °C; LC-MS: 333, 335 (MH+); anal. RP-HPLC: 4.07 min.).
Example 72
4- (6.7-Dimethvl-2.3-dihvdro-indol-1-vl)-pvridor3.4-d1pvrimidine hydrochloride
To 4-chloro-pyrido[3,4-d]pyrimidine (200 mg, 1.21 mmol) in isopropanol (3 mL) was added 6,7-dimethylindoline (211 mg, 1.44 mmol) and pyridine (190 mg, 2.41 mmol). The reaction mixture was heated to reflux under an atmosphere of dry nitrogen for 6 hours. Solvent was removed in vacuo and the residue was dissolved in CHCI3 and washed with saturated aqueous sodium carbonate. The organic phase was dried over sodium sulfate concentrated in vacuo, and flash chromatographed on silica in 45% acetone/hexanes to afford 60 mg of the free base of the title product (LC-MS: 278 (MH+). This material was dissolved in a minimum volume of 10% methanol in methylene chloride and 1 mole equivalent of HCI in ether was added dropwise with stirring. The reaction mixture was diluted with four volumes of ether and the
If c
a c
c a
c <
AP 00637
-47precipitated title product was filtered and dried in vacuo (58 mg; M.P. 248°C; GC-MS: 277 (M+); anal. RP-HPLC: 4.06 min.)
Example 73 (3-Ethvnvl-phenvl) f-pyrido i3,4-d1 pvrim id in-4-vl Famine hydrochloride
To4-chloro-pyrido[3,4-d]pyrimidine(250mg, 1.50 mmol) in N-methylpyrrolidin-2one (0.5 mL) was added 3-ethynylaniline (212 mg, 1.81 mmol) and pyridine (237 mg, 3.0 mmol). The reaction mixture was heated to 80°C under an atmosphere of dry nitrogen for 3hours. The reaction mixture was dissolved in CHCI3 and washed with saturated aqueous sodium carbonate, and brine. The organic phase was dried over sodium sulfate , concentrated in vacuo, and flash chromatographed on silica with a gradient of 40% to 70% acetone/hexanes to afford 120 mg of product. This product was dissolved in a minimal amount of CHCI3, titrated with 1 eq. HCl in ether, and dilution with ether. The resultant precipate was filtered and dried in vacuo to yield the yellow title product (133 mg; M.P. 233-235°C; LC-MS: 247 (MH+); anal. RP-HPLC: 3.45 min.).
Example 74 (Benzorb1thlophen-5-vlH-pvridor3.4-dlpyrimldin-4-vl-)amine hydrochloride;
To4-chloro-pyrido[3,4-d]pyrimidine (250 mg, 1.50 mmol) in N-methylpyrrolidin-2one (0.5 mL) was added benzo[b]thiophen-5-yl-amine (270 mg, 1.81 mmol) and pyridine (237 mg, 3.0 mmol). The reaction mixture was heated to 80°C under an atmosphere of dry nitrogen for 3 hours. The reaction mixture was dissolved in CHCI3 and washed with saturated aqueous sodium carbonate and brine. The organic phase was dried over sodium sulfate, concentrated in vacuo, and flash chromatographed on silica in 40% acetone/hexanes to afford 180 mg of product. This product was dissolved in a minimal amount of CHCI3, titrated with 1 eq. HCl in ether, and dilution with ether. The resultant precipate was filtered and dried in vacuo to yield the yellow title product (188 mg; M.P. 280-282°C; LC-MS: 279 (MH+); anal. RP-HPLC: 3.63 min.).
Example 75 (3-Ethynvl-phenvD-(6-methvl-pvridor3.4-d1pyrimIdin-4-vl)-amine hydrochloride;
This material was prepared from 4-chloro-6-methyl-pyrido [3,4-d] pyrimidine (1.0 eq.) and 3-ethynylaniline (1.1 eq.) as described for Example 74. After extraction chromatography of the residue on silica in 20% to 80% acetone/hexanes afforded 166
AP/P/ 9 6 / 0 0 80 5
AP 00637
-48mg of the title product as its free-base which was converted to the title product (M.P. 25O-252°C; LC-MS: 261 (MH+); anal.RP-HPLC: 3.69 min.).
Example 76
4-(6-Chloro-2.3-dlhvdro-lndol-1-vl)-6-methvl-pyridof3.4<npvrlmidine
This material was produced from 4-chloro-6-methyl-pyrido [3,4-d] pyrimidine (1.0 eq.) and 6-chloroindoline (1.1 eq.) as described for Example 74. Preparative reversedphase (C18) chromatography utilizing a gradient of 15% to 70% acetonitrile/pH4.5, 50 mM ammonium acetate followed by lyophilization of the appropriate fractions afforded the title product (30%) (M.P. 232-234°C; LC-MS: 297 (MH+); anal.RP-HPLC: 4.33 min.).
Example 77 (1H-lndol-5-vl)-(6-methvl-pvrldor3.4-d1pyrlmldln-4-vO-amlne methanesulfonate ι
This material was produced from 4-chloro-6-methyl-pyrido [3,4-d] pyrimidine (1.0 eq.) and 5-aminoindole (1.1 eq.) as described for Example 74. Preparative reversedphase (C18) chromatography utilizing a gradient of 15% to 70% acetonitrile/pH4.5,
50mM ammonium acetate followed by lyophilization of the appropriate fractions afforded free-base (30%) of the title product (M.P. 262-263°C; LC-MS: 276 (MH+); anal.RP-HPLC: 2.98 min.). This material was converted to thte title product by dissolution in a mimimal amount of CHCI3 followed by addition of 1 eq. of methane sulfonic acid. Dilution with ether precipitated the title product which was filtered and 20 dried in vacuo (M.P. 317-318°C).
Example 78 (3-Ethvnvl-phenyl)-(5-methvlsulfanvl-7H-pvrrolor2.3-d1pvrimidin-4-vl)-amlne
To 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (0.18 g, 0.77 mmol) in dry THF (2 ml), cooled in a dry ice-acetone bath, was added dropwise n-butyllithium (0.77 ml,
1.9 mmol, 2.5 M in hexanes). The mixture was stirred for 1 hour, then dimethyldisulfide (0.077 mL, 0.77 mmol) suspended in dry THF (1 ml) was added. The solution was stirred for 2.5 hours at -78°C and then diluted with aqueous NH4CI. The phases were separated and the water extracted 2 times with ethyl acetate. The combined organic phases were dried over Na2SO4, and concentrated in vacuo to afford 4-chloro-530 methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine as an orange solid (150 mg).
To 4-chloro-5-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine (150 mg, 0.75 mmol) in dry methanol (2 ml) was added m-aminophenyl acetylene (110 mg, 0.90 mmol). The solution was heated in a sealed pressure tube at 125°C for 5.5 hours. The reaction f * o /d/dV
AP 00637
-49mixture was cooled to ambient temperature, filtered with a small amount of methanol and dried in vacuo to afford the title compound as a tan powder (57 mg, 27%). TSMS: 281 (MH+); anal. RP18-HPLC RT: 4.74 min.
Preparation 1
Pvridor4,3-<f|pvrimldone from 4-amlnonlcotlnlc acids
6-Methyl-4-aminonicotinic acid (420 mg, 2.74 mmol) and dry formamide were heated to 165°C for 6 hours under N2. The reaction mixture was cooled to room temperature and the formamide was removed in vacuo. The remaining residue was purified by reverse-phase HPLC (linear gradient 5-100% acetonitrile at pH 4.50, 50 mM ammonium acetate over 1 hour with a flow rate of 23.0 mL/min.) to afford the title product (50% ; GCMS RT= 1.48 min.; M+= 195).
Preparation 2
6-Methvl-pyrIdor3.4-cnpvrlmld-4-one
5-Amino-2-methyl-4pyridinecarboxylic acid was prepared according to Palt, K.; 15 Celadnik, M.; Dvorackova, D.; Kubaia, E., Cesk. Farm., 32(8), 275-278 (1983). This carboxylic acid was converted to the title product by heating in formamide at 165°C according to the procedure of Robins, R.; Hitchings, G.; J. Am. Chem. Soc. 77, 2256 (1955).

Claims (18)

  1. CLAIMS Q*c dcckuc ti>4t whut i/ wc ciiirn u
    1.
    A compound of the formula and stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Y together with the carbons to which it is attached form a 5 or 6 membered, aromatic ring wherein said ring is optionally substituted with (R3)p and/or R4 groups and comprises one to three nitrogen and optionally one heteroatom selected from S and O;
    Z is NR1R2 wherein R1 is H and R2 is phenyl substituted by (R5)m or Q or R1R2N is a group of the formula (R5), μ
    c fi fi fi (j c
    w (
    w (
    wherein the dotted line represents an optional double bond;
    each R3 is attached to a carbon atom in Y and is independently selected from
    a. phenyl, trifluoromethyl, halo, nitro, hydroxy, amino, cyano, (C,-C4)alkyi, (Cr 25 CJalkoxy, (C,-C4)aikoxycarbonyl, (C,-C4)alkanoyloxy, (C,-C4)alkanoylamino, carboxy, phenoxy, benzoyloxy, carbamoyl, mono-N- or di-N-N-di-(C,-C4)alkylcarbamoyl, mono-Nor di-N,N-(C,-C4)aikyIamino, mono-N or di-N,N-(hydroxy(C2-C4)alkyl)amino, mono-N or di-N,N-((C,-C4)alkoxy(C2-C4)alkyl)amino, anilino, pyrrolidin-1-yl, piperidin-1 -yl, morpholino, piperazin-1-yl, 4-(C,-C4)alkylpiperazin-1-yl, pyridyl, pyrrolo, imidazolo,
    30 thiazolo, benzimidazolo, pyridonyi, (C1-C4)aikylthio, phenylthio, or such groups substituted on (C,-C4)alkyl;
    b. hydroxyiCj-CJalkoxytC^CJalkyl, (C1-C4)aikoxy-(C2-C4)alkoxy-(C1-C4)alkyl, hydroxy(C2-C4)alkylthio(C1-C4)aikyl, (C1-C4)alkoxy(C2-C4)alkylthio(C1-C4)alkyl,
    AP 00637
    -51hydroxyamino, benzoylamino, mono-N or di- N.N-fC^-CJalkylcarbamoylmethylamino, carbamoylmethylamino, (C,-C4)alkoxycarbonylamino, (C,-C4)alkanoylamino, carboxymethylamino, (C,-C4)alkoxycarbonylmethylamino, (C,-C4)alkoxyamino, (C2C4)alkanoyloxyamino, phenylfC^C^alkylamino, (C^CJalkylsulphonylamino,
    5 benzenesulphonamido, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, ureidoXC^CJalkoxytC^CJalkylcarbonylaminoXC^-CJalkylsulfinyl.iC^CJalkylsulionyl, (C,-C4)alkoxy(C2-C4)aikylthio, mono-, di- or trifluoromethyloxy, (C,-C4)alkylenedioxy, benzyloxy, guanidino, aminocarbonyl, mono-N- or di-N.N-fC^CJalkylaminocarbonyl, phenyl(C,-C4)alkoxy, carboxymethoxy, (C1-C4)alkoxycarbonylmethoxy,
    10 carbamoylmethoxy, mono-N or di-N,N-(C,-C4)alkyl carbamoyl methoxy, mono-N- or diN,N-(hydroxy(C2-C4)aIkyl)carboxamido, mono-N- or di-N.N-^C^-CJalkoxy (C2C4)alkyl)carboxamido or bis((C,-C4)alkanesulfonyl)amido; or c. (C2-C4)alkoxy, (C2C4)alkylthio, (C2-C4)alkanoyloxy, (C2-C4)alkylamino, (C^CJalkylfCT-CJalkylenedioxy, (C2-C4)alkanoylamino, (C2-C4)alkenyl, or (C2-C4)alkynyl; each such group substituted
    15 with amino, halo, hydroxy, (C2-C4)alkanoyloxy, (C,-C4)alkoxy, mono-N- or di-N,N-(C,C4)alkylamino, mono-N or di-N,N-(hydroxy(C2-C4)alkyI)amino, mono-N or di-N,N-((C,C4)alkoxy(C2-C4)alkyl)amino, (C^CJalkanoylamino, phenoxy, anilino, imidazol-1-yl, phenylthio, piperidino, pyridyl, carboxy(C,-C4)alkylthio(Ct-C4)alkoxy, morpholino, piperazin-1 -yl-.^Cj-CJalkylpiperazin-l -yl-, carboxy, (C^CJalkoxycarbonyl, carbamoyl,
    20 mono-N- or di-N.N-iC^CJalkylcarbamoyl, carboxamido, mono-N- or di-N,N-(C,C4)aikylcarboxamido or mono-N- or di-N,N-(hydroxy(C2-C4)alkyl)carboxamido; and any phenyl in an R3 substituent is optionally mono- or di- substituted with halo, nitro, trifluoromethyl, hydroxy, (C,-C4)alkoxy, (C,-C4)alkyl, amino, mono-N-alkylamino, or N,Ndialkylamino;
    25 R4 is attached to a N-atom in Y and is independently selected from:
    hydrogen, (CrC4)alkyl, (C,-C4)alkoxycarbonyl, (C,-C4)alkanoyl, (C,-C4)alkylsulfonyl, arylsuifonyl, allyl; or a (C2-C4)alkyl, (C2-C4)alkanoyl, or (C2-C4)alkoxycarbonyl1 (C2CJalkylsulfonyl, each such group substituted with amino, halo, hydroxy, (C2C4)alkanoyloxy, (C,-C4)alkoxy,mono-N-ordi-N.N-^-CJalkylamino, mono-Nordi-Ν,Ν30 (hydroxy(C2-C4)alkyl)amino, mono-N or di-N,N-((C,-C4)aIkoxy(C2-C4)alkyl)amino, (C,C4)aikanoylamino, phenoxy, anilino, imidazol-1-yl, phenylthio, piperidino, morpholino, piperazin-1-yl-, 4-(C,-C4)alkylpiperazin-1-yl-, phenyl, pyridyl, pyrrolo, imidazolo, thiazolo, benzimidazolo, pyridonyl, carboxy, (C,-C4)alkoxycarbonyl, carbamoyl, mono-N- or diAP/P/ 96 / 0 0 80 5
    AP 00637
    -52N,N-(C,-C4)alkylcarbamoyl, carboxamido, mono-N- or di-N,N-(C,-C4)alkylcarboxamido or mono-N- or di-N,N-(hydroxy(C2-C4)alkyl)carboxamido; and any phenyl in an R4 substituent is optionally mono- or di- substituted with halo, nitro, trifluoromethyl, hydroxy, (C,-C4)alkoxy, (C,-C4)alkyl, amino, mono-N-alkylamino, or Ν,Ν-dialkylamino;
    5 but specifically R* is not furanosyl, pyranosyl, or cyclopentyl;
    each R5 is independently selected from mono-, di- or tri-fluoromethyl, halo, nitro, hydroxy, amino, azido, isothiocyano, (C^CJalkyl, phenyl, thienyl, (0,-CJalkoxy, benzyloxy, phenoxy, (C2-Ce)alkenyl, (C2-Ce)alkynyl, (C,-C4)alkylenedioxy, cyano, benzoylamino.trifluoromethylcarbonylamino, (C,-C4)alkanoylamino, (C,-C4)alkanoyl, N10 mono- or N,N-di-(C,-C4)alkylamino, (C,-C4) alky Isu If o ny I ami no, trifluoromethylsulfonylamino, (C^CJalkylthio, (C,-C4)alkylsulfinyl or(C1-C4)alkylsulfonyl, pyrrol-1-yl, piperidin-1-yl or pyrrolidin-1-yl, said phenyl, benzyloxy, phenoxy and UP benzoylamino optionally mono-substituted with halo, nitro, trifluoromethyl, hydroxy or c
    OI (C^CJalkyl and said (C^CJalkylenedioxy is linked at both ends to adjacent carbons
    15 on the benzene moiety or two R5,s with the carbons atoms to which they are attached «ί form a group selected from imidazolyl, pyrrolo and pyrazolyl;
    . «J each Re is independently selected from hydroxy, amino, N-mono- or N,N-di-(C,- c
    C4)alkylamino, sulfo, or (C,-C4)aikoxy (provided that such groups are not attached to ’ a ring carbon which is directly adjacent to the ring N-), or R® for each occurrence is j
    20 independently carboxy, hydroxy(C,-C4)alkyl, (C,-C4)alkoxy(C,-C4)alkyl, amino^- , C4)alky1, mono-N- or di-N.N-iC^CJalkylaminoiC^CJalkyl, morpholino (C^CJalkyl, 4(C,-C4)alkyl-piperazin-1-yl(C,-C4)alkyl, carboxy(C,-C4)alkyl, (C ,-C4) alkoxy carbonyl, sulfo^-CJalkyl, pyridyl(C,-C4)alkyl or (C,-C4)aJkyl;
    m is an integer from 1 to 3;
    25 n is 0, 1 or 2;
    p is 0 or an integer from 1-3;
    with the proviso that when Y, in the direction shown by the arrow in formula I, is -CR3=N-CR3=CR3-, p = 0, m = 1 and Z is substituted phenyl then R5 is not 4ethoxy, 4-methoxy, 4-trifluoromethoxy, 4-t-butyl or 4-isopropyl;
    30 Q is a 9- or 10-membered bicyclic heteroaryl cyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl,
    AP 06637
    -53(C,-C4)alkyl, (C,-C4)alkoxy, (C,-C4)alkylamino, di-[(C,-C4)alkyl]amino. (C2CJalkanoylamino, (C2-C4)alkenyl and (C2-C4)alkynyl with the proviso that when Y, in the direction shown by the arrow in formula I, is -NR4-CR3=CR3-, R3 = CH3 and R4=H, then R5 is not 4-CH3,3,5-(CH3)2,2,6-(CH3)2,2-C2H6,4-C2H6,4-n-C4He, 2-CI, 4-CI, 3,4-CI2,2-F,
    5 or 3-CF3, with the proviso that where Y isapyrrotoringsuchthatapyndopynimdinebicyelicnng is formed, the nitrogen on the pyrrolo portion of the ring is substituted only with a hydrogen.
  2. 2. The compound of claim 1 wherein Y, in the direction shown by the arrow in formula I, is selected from -N=CR3-NR4-, -CR3=CR3-NR4-, -NR4-CR3=CR3-, -N=NNR4-, -NR4-N = N-, -CR3=N-NR4-, NR4-N=CR3, -CR3=N-CR3=CR3- and
    1 o -CR3=CR3-N=CR3-> with the proviso that where Y is a pyrrolo ring such that a pyrrotapyrimidine bicyclic ring is formed, the nitrogen on the pyrrolo portion of the ring is substituted only with a hydrogen.
  3. 3. The compound of claim 2 wherein Y in the direction shown by the arrow in formula I, is selected from -CR3=CR3-NR4-, -NR4-CR3=CR3- and -CH=CR3-N=CH-, 5 with the proviso that where Y is a pyrrolo ring such that a pyrndopyrimidine bicyclic ring is formed, the nitrogen on the pyrrolo portion ofthering is substituted only with a hydrogen.
  4. 4. The compound of claim 3 wherein each R3 is independently selected from hydroxy, (C,-C4)aJkoxy, hydroxy(C2-C4)aikoxy, amino(C2-C4)alkyl, amino(C2C4)aikoxy, (C,-C4)alkoxy(C2-C4)alkoxy, hydroxy(C1-C4)alkyl(C1-C4)alkylenedioxy, (C,20 C4)aIkoxy(C,-C4)alkyl(C,-C4)aIkylenedioxy, mono-N- or di-N.N-iC^CJalkylaminofCjCJalkoxy, 3- or 4-(C,-C4)alkoxy-(2-hydroxy)-(C3-C4)alkoxy, carboxy(C,-C4)alkoxy, morpholino(C2-C4)aIkoxy, imidazol-1 -yl(C2-C4)aIkoxy, 4(C,-C4)alkylpiperazin-1 -yl-(C2C4)alkoxy, (C^-CJalkoxy^-CJaJkanoyloxy, nitro, hydroxylamino, amino, phenyl, pyridyl, pyrrolo, imidazolo, thiazolo, benzimidazolo, pyridonyl, mono-N- or d!-N,N-(C,25 C4)alkylamino, (C,-C4)alkanoylamino, hydroxy(C2-C4)alkylamino, (C,-C4)alkoxy(C2CJalkylamino, (C,-C4)alkylsulfonamldo, morpholino, (C,-C4)alkyl-plperazln-1-yl. bls(C,CJalkanesulfonamido, di-N,N-(C,-C4)alkylamino{C2-C4)alkylamino, (C,-C4)alkylamino(C2C4)alkylamino, piperidin-1-yl, imidazol-1-yl, pyrrolidin-1-yl, (C,-C4)alkoxy(C,CJalkylcarbonylamino, carboxy, (C,-C4)alkoxycarbonyl, (C^-CJalkoxycarbonyKC,30 C4)alkoxy, amido, mono-N- or di-N,N-(C,-C4)alkylaminocarbonyl, mono-N- or di-N,N(hydroxy(C2-C4)alkyl)aminocarbonyl, (C,-C4)alkyl, hydroxy(C,-C4)alkyl, mono-N- or diS 08 0 0 / 96 /d/dV
    AP 00637
    -53aN,N-((C1-C4)alkoxy(C,-C4)alkyl)amino(C,-C4)alkyl, mono-N- or di-N,N-(C,CJalkylaminofCj-CJalkyl, ((/-CJalkanoylaminoiCZ-CJalkyl, (C,-C4)alkoxy(C2C4)alkoxy(C,-C4)aJkyl, (C,-C4)alkylthio, (C,-C4)alkoxy(C2-C4)alkylthio or hydroxy(C2CJalkylthio; and R4 is selected from hydrogen, benzyl, phenyl, a (C2-C4)alkyl, 5 hydroxy(C2-C4)alkyl, or hydroxy(C2-C4)alkyl, amino(C2-Ce)alkyl, (C2-C4)alkoxycarbonyl each such group substituted with amino, halo, hydroxy, (C2-C4)alkanoyloxy, (C,C4)alkoxy, mono-N- or di-N.N-iCZ-CJalkylamino, mono-N or di-N,N-(hydroxy(C2C4)alkyl)amino, mono-N or di-N,N-((C,-C4)alkoxy(C2-C4)alkyl)amino, sulfonylaryl(C,C4)alkylamine, (C,-C4)aikanoylamino, imidazol-1-yl, piperidino, morpholino, piperazin-11 o y1* 4-(C,-C4)alkylpiperazin-1 -yl-, pyridyl, pyrroio, imidazolo, thiazolo, pyridonyl, carboxy, (C,-C4)alkoxycarbonyl, carbamoyl, mono-N- or di-N,N-(C,-C4)alkylcarbamoyl, carboxamido, mono-N- or di-N,N-(C,-C4)aikylcarboxamido or mono-N- or di-N,N(hydroxy(C2-C4)alkyl)carboxamido, with the proviso that where Y is a pyrroio ring such that a pyrrolopyrimidine bicyclic ring is formed, the nitrogen on foe pyrrole portion of foe ring is
    15 substituted only with a hydrogen.
  5. 5. The compound of claim 4 wherein Y, in the direction shown by the arrow in formula I, is selected from -NR4-CR3=CR3-, -CH=CR3-N=CH- and -CR3=CR3-NR4-, with the proviso that where Y is a pyrroio ring such that a pyrrolopyrirnidine bicyclic ring is formed, the nitrogen on foe pyrroio portion offoe ring is substituted only with a hydrogen
    2 θ
  6. 6. The compound of claim 5 wherein Y, in the direction shown by the arrow in formula I, is -CR3=CR3-NR4- and R4 is hydrogen, with foe proviso that where Y isa pyrroio ring such that a pyrrolopyrimidine bicyclic ring is formed, foe nitrogen on the pyrroio portion offoe ring is substituted only with a hydrogen
    AP/P/ 96/00805
  7. 7. The compound of claim 2 wherein R’R’N is (R6)_ and R5, R®, m and n are as defined above.
    AP 00637
    -548. The compound of claim 7 wherein each R5 is independently selected from 4-hydroxy, 4-amino, 5-fluoro, 5-hydroxy, 5-amino, 6-haio, 6-methyl, 6-ethenyl, 6ethynyl, 6-nitro and 7-methyl and each R® is independently selected from hydroxy, amino, N-mono- or N,N-di-(C,-C4)alkylamino, sulfo, or (C,-C4)alkoxy (provided that such 5 groups are not attached to a ring carbon which is directly adjacent to the ring N-), or R® for each occurrence is independently carboxy, hydroxy(C,-C4)aikyl, (Cl-C4)alkoxy(C1C4)alkyl, amino(C,-C4)alkyl, mono-N- or di-N.N-iC^CJaikylaminoiC^CJalkyl, morphoiino (C,-C4)alkyl, 4-(C,-C4)aikyl-piperazin-1-yl(C,-C4)aikyl, carboxy^-C^alkyl, (C,-C4)alkoxycarbonyl, sulfo(C,-C4)alkyl, pyridyi(C,-C4)alkyl and (C,-C4)alkyl.
  8. 10 9. The compound of claim 2 wherein R1 is H and RJ is (RB)m-substituted phenyl wherein R® and m are as defined above.
    10. The compound of claim 9 wherein each R5 is independently selected from 4-fluoro-3-chloro, 3-trifluoromethyl, 4-fluoro-3-trifluoromethyl, 3-nitro-4-chloro, 3nitro-4-fluoro, 4-fluoro-3-bromo, 3-iodo-5-amino, 3-methyi-4-fluoro, 4-amino, 3-fluoro, 3hydroxy, 3-amino, 3-halo, 3-methyl, 3-ethenyl, 3-ethynyl, 3-nitro and 4-methyl.
    AP/P/ 96/00805
    AP 00637
    -5511. The compound of claim 2 wherein R1 is H and R2 is Q.
  9. 12. The compound of claim 11 wherein Q is selected from pyrrolo, 4-, 5-, 6indolyl, 1 H-benzimidazol-4-yI, 1 H-benzimidazol-5-yl, 1 H-indazol-4-yl, 1 H-indazol-5-yl, 1Hindazol-6-yl, 1 H-indazol-7-yl, 1 H-benzotriazol-4-yl, 1 H-benzotriazol-5-yl, 1 H-benzotriazol5 6-yl, 5- or 6-benzoxazoiyl, 5- or 6-benzothiazolyl, benzo[c] [2,1,3]thiadiazol-4-yl, 2-, 3-,
    4-, 5-, 6-, 7- or 8-quinoiyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinoiyl, 4-, 5-, 6-, 7- or 8cinnolinyl, 5-, 6-, 7- or 8-quinazolinyl, or 2-, 5-, or 6-quinoxalinyl, which may optionally bear one or two substituents selected from fluoro, bromo, chloro,methyl, ethyl, ethenyl, ethynyl and methoxy.
    10 13. The compound of claim 12 wherein Q is selected from pyrrolo 5-indolyl,
    1 H-indazol-5-yl, 1 H-benzotriazol-5-yl, 6-benzothiazolyl, benzo [c] [2,1,3]thiadiazol-4-yl, 5tr quinolyl, 6-quinolyl, 8-quinolyl, 5-isoquinolyl, or 5-quinoxalinyl, which may optionally bear one or two substituents selected from fluoro, bromo, chloro,methyl, ethyl, ethenyl, β ethynyl and methoxy. C
  10. 15 14. The compound of claim 1 selected from the group consisting of (3-ethynyi-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine hydrochloride; (3-chloro-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine hydrochloride; 4-(6-chloro-2,3-dihydro-indo!-1-yl)-7H-pynOlo[2,3-d]pyrimidine hydrochloride; (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-m-tolyl-amine hydrochloride;
    20 (1H-indol-5-yi)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine hydrochloride;
    (6-methylindolin-1-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; (benzo[b]thien-5-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; (6-chloro-5-fluoroindolin-1-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; (1H-indazol-5-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
    25 1 -(4-m-tolylamino-pyrrolo[2,3-d]pyrimidin-7-yI)-ethanone hydrochloride;
    (5-iodo-7H-pyrroloI2,3-d]pyrimidin-4-yl)-m-tolyl-amine;
    (3-chloro-phenyl)-(1 H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-amine hydrochloride; (3-chloro-phenyl)-pyrido[4,3-d]pyrimidin-4-yl-amine hydrochloride;
    (1 H-indol-5-yl)-pyrido[4,3-d]pyrimidin-4-yl-amine hydrochloride;
    30 (3-ethynylphenyl)-(7-methyl-pyrido[4,3-d]pyrimidin-4-yI)-amine hydrochloride;
    (3-chloro-phenyl)-(7-methyl-pyrido[4,3-d]pyrimidin-4-yl)-amine hydrochloride;
    AP 00637
    -56(3-ethynyl-phenyl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine hydrochloride; (6-bromo-5-fluoroindolin-1-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine; (6-chloro-5-fluoroindolin-1-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine; (1H-indazol-5-yl)-(pyrido[4,3-d]pyrimidin-4-y1)-amine;
    5 (benzo[b]thien-5-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine;
    (3-methyl-4-hydroxyphenyl)(6-methylpyrido[4,3-d]pyrimidin-4-yl)-amine;
    (6-iodoindolin-1-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine;
    (benzo [b]thien-5-yl)-(pyrido[4,3-d]pyrimidin-4-yl)-amine; (3-ethynyl-phenyl)-(9H-purin-6-yl)-amine;
    10 (1 H-indol-5-yI)-(9H-purin-6-yI)-amine hydrochloride;
    (3-chloro-phenyI)-(9H-purin-6-yl)-amine hydrochloride; 4-(6-chloro-2,3-dihydro-indol-1-yl)-pyrido[3,4-d]pyrimidine; (pyrido[3,4-d]pyrimidin-4-yl)-(m-tolyl)-amine; (1H-indazol-5-yl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine;
    15 (1 H-indol-5-yl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine;
    (phenyl)-(pyrido[2,3-d]pyrimidin-4-yl)-amine; (3-chloro-phenyl)-(pyrido[2,3-d]pyrimidin-4-yl)-amine; (3-chloro-phenyl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine; (3-bromo-phenyl)-(pyrido[3,4-d]pyrimidin-4-yl)-amine;
    20 (phenyl)-(pyrido [3,4-d] pyrimidin-4-y1)-amine;
    4-(6-chloro-2,3-dihydro-indol-1-yi)-pyrido [3,4-d] pyrimidine; (pyrido[3,4-d]pyrimidin-4-yi)-(m-tolyl)-amine;
    (1H-indazol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
    (1H-indol-5-yI)-pyrido[3,4-d]pyrimidin-4-yl-amine;
    25 phenyl-pyrido[2,3-d]pyrimidin-4-yi-amine;
    (3-chloro-phenyl-pyrido [2,3-d] pyrimidin-4-yl-amine; (3-chloro-phenyl-pyrido[3,4-d]pyrimidin-4-yl-amine;
    (3-bromo-phenyl-pyrido [3,4-d] pyrimidin-4-yl-amine;
    phenyl-pyrido[3,4-d]pyrimidin-4-yi-amine;
    30 (7-benzenesulfonyi-7H-pyrrolol2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine;
    4-(6-chloro-2,3-dihydro-indoI-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-ol;
    (3-ethynyl-phenyl)-[7-(2-morpholin-4-yl-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]AP/P/ 96/00805 amine;
    AP 00637
    -57(3-ethynyl-phenyl)-[7-(2-methoxy-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine;
    (3-ethynyl-phenyl)-{7-[2-(2-methoxy-ethoxy)-ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}-amine;
    (7-allyI-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine hydrochloride;
    5 (3-ethynyi-phenyl)-(7-methyl-pyrrolo[2,3-d]pyrimidin-4-yl)-amine hydrochloride;
    (5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyi)-amine; (3-ethynyl-phenyI)-(5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; 4-(3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid; (3-ethynyl-phenyl)-(5-methyl-7H-pyrrolo [2,3-d]pyrimidin-4-yI)-amine hydrochloride;
    N-(5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-m-tolyl-acetamide; 4-(3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid methyl ester hydrochloride;
    (1 H-indazol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
    15 benzo[b]thiophen-5-yl-(6-methyt-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
    (3-ethynyl-4-fluoro-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
    2-methyl-4-(6-methyl-pyridoI314-d]pyrimidin-4-ylamino)-phenol dihydrochloride; 4-(4-bromo-7-methyl-2,3-dihydro-indo,-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine hydrochloride;
    20 4-(6-bromo-7-methyl-2,3-dihydro-indol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine hydrochloride;
    4-(6-bromo-5-fluoro-2,3-dihydro-indol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine hydrochloride;
    (3-chloro-4-fluoro-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine 25 hydrochloride;
    (6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-(3-trifluoromethyl-phenyl)-amine hydrochloride;
    (4-fluoro-3-methyl-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
    30 2-iodo-4-(6-methyl-pyrido[3,4-d]pyrimidin-4-ylamino)-phenol hydrochloride;
    (4-bromo-3-fluoro-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine hydrochloride;
    4-(6,7-dimethyl-2,3-dihydro-indoI-1-yl)-pyrido[3,4-d]pyrimidine hydrochloride;
    S 0 8 0 0 / 9 6 /d/dV
    AP 00637
    -58(3-ethynyl-phenyl)-pyrido[3,4-d]pyrimidin-4-yl-amine hydrochloride; benzo [b]thiophen-5-yl-pyrido [3,4-d]pyrimidin-4-yl-amine hydrochloride; (3-ethynyl-phenyl)-(6-methyl-pyrido [3,4-d] pyrimidin-4-yi)-amine hydrochloride; 4-(6-chloro-2,3-dihydro-lndol-1-yl)-6-methyl-pyrido[3,4-d]pyrimidine;
    5 (3-ethynyl-phenyl)-(5-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
    (3-ethynyl-phenylamino)-(7H-pyrrolo[2,3-d]pyrimidin-5-yl-carbonitrile.
    and (1H4ndol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine methanesuffonate.
    15. The compound according to claim 14 selected from the group consisting
    10 of (1H-indol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
    (3-ethynyl-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
    (3-ethynyl-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
    (3-chloro-phenyl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
    15 (3-ethynyl-phenyl)-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- amine;
    4-(3-ethynyl-phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylicacid methyl ester;
    4-(3-ethynyl-phenylamino)-7H-pyrrolo[213-d]pyrimidine-5-carbonitrile;
    (1H-indol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
    20 (3-chloro-4-fluoro-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)- amine;
    benzo [b]thiophen-5-yl-(6-methyl-pyrido [3,4-d] pyrimidin-4-yl)-amine; (3-ethynyl-phenyl)-pyrido[3,4-d]pyrimidin-4-yl-amine;
    (4-fluoro-3-methyl-phenyl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)- amine hydrochloride;
    25 4-(6-chloro-2,3-dihydro-indol-1-yl)-pyrido[3,4-d]pyrimidine;
    pyrido[3(4-d]pyrimidin-4-yi-m-tolyl-amine;
    (6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-(3-trifluoromethyl-phenyl)- amine hydrochloride;
    (1H-indazol-5-yl)-(6-methyl-pyrido[3,4-d]pyrimidin-4-yl)-amine;
    30 (3-ethynyl-phenyl)-(5-methylsulfanyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
    (1H-indol-5-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4--yl)-amine; (5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-ethynyl-phenyl)-amine; and (3-ethynyl-phenylamino)-(7H-pyrrolo[2,3-d]pyrimidin-5-yl-carbonitrile.
    AP/P/ 9 6 / 0 0 8 0 5
    AP 00637 wherein the dotted circle indicates that the ring is aromatic and W, in the direction indicated by the arrows, is selected from -CH=C(CH3)-N=CH-, -CH=N-C(CH3)=CHand =C(CH3)-NH-CH=.
  11. 17. The compound of claim 16 wherein W is -CH=C(CH3)-N=CH-.
  12. 18. The compound of claim 16 wherein W is -CH=N-C(CH3)=CH-.
  13. 19. The compound of claim 16 wherein W is =C(CH3)-NH-CH=.
  14. 20. A method of treating hyperproliferative disorders which comprises administering to a mammal in need of such treatment a hyperproliferative disorder treating amount of a compound of claim 1.
  15. 21. A method as recited in claim 20 wherein the hyperproliferative disease is cancer.
    20
  16. 22. A method as recited in claim 21 wherein the disease is brain, lung, squamous cell, bladder, gastric, pancreatic, hepatic, renal, colorectal, breast, head, prostate, neck, oesophageal, gynecological or thyroid cancer.
  17. 23. A method as recited in claim 20 wherein the hyperproliferative disorder is noncancerous.
  18. 25 24. A method as recited in claim 23 wherein the noncancerous hyperproliferative disorder is psoriasis or benign prostatic hyperplasia.
    25. A pharmaceutical composition for the treatment of hyperproliferative disorder in a mammal which comprises a hyperproliferative disease treating amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
APAP/P/1996/000805A 1995-06-07 1996-05-09 Heterocyclic ring-fused pyrimidine derivatives. AP637A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/007881 WO1996040142A1 (en) 1995-06-07 1995-06-07 Heterocyclic ring-fused pyrimidine derivatives
HU9601559A HUP9601559A3 (en) 1995-06-07 1996-06-06 Heterocyclic ring-fused pyrimidine derivatives, pharmaceutical compositions containing the same and intermediates

Publications (2)

Publication Number Publication Date
AP9600805A0 AP9600805A0 (en) 1996-07-31
AP637A true AP637A (en) 1998-04-08

Family

ID=89994036

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000805A AP637A (en) 1995-06-07 1996-05-09 Heterocyclic ring-fused pyrimidine derivatives.

Country Status (32)

Country Link
EP (1) EP0831829B1 (en)
JP (1) JP3290666B2 (en)
CN (1) CN1141298A (en)
AP (1) AP637A (en)
AR (1) AR002746A1 (en)
AT (1) ATE247469T1 (en)
AU (1) AU5479196A (en)
BR (1) BR9602695A (en)
CA (1) CA2223081C (en)
CO (1) CO4440628A1 (en)
CZ (1) CZ164196A3 (en)
DE (1) DE69531558T2 (en)
DK (1) DK0831829T3 (en)
ES (1) ES2203642T3 (en)
FI (1) FI974443A (en)
HR (1) HRP960269A2 (en)
HU (1) HUP9601559A3 (en)
IL (1) IL118487A0 (en)
MA (1) MA26409A1 (en)
MX (1) MX9709867A (en)
NO (1) NO962386L (en)
NZ (1) NZ286755A (en)
OA (1) OA10460A (en)
PL (1) PL314641A1 (en)
PT (1) PT831829E (en)
RU (1) RU2136683C1 (en)
SG (1) SG45483A1 (en)
SI (1) SI9600184A (en)
SK (1) SK72996A3 (en)
TR (1) TR199600474A2 (en)
WO (1) WO1996040142A1 (en)
ZA (1) ZA964725B (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (en) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative activity
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
WO1996031510A1 (en) * 1995-04-03 1996-10-10 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE69613367T2 (en) * 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje CHINAZOLIN DERIVATIVES
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DK0836605T3 (en) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidines and Methods for their Preparation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69712745T2 (en) * 1996-01-23 2002-10-31 Novartis Ag, Basel PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
ES2297864T3 (en) 1996-08-23 2008-05-01 Novartis Ag REPLACED PIRROLOPIRIMIDINES AND PROCESSES FOR THEIR PREPARATION.
CA2266519C (en) 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
WO1998023613A1 (en) 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
EP1012151B1 (en) * 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
PL340589A1 (en) * 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
JPH11236333A (en) * 1997-12-30 1999-08-31 Pfizer Prod Inc Imidazolin-4-one derivative as anticancer agent
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
RS50087B (en) 1998-06-19 2009-01-22 Pfizer Products Inc., Pyrolo (2,3-d) pyrimidine compounds
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6174903B1 (en) 1998-12-28 2001-01-16 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
EP1192151B1 (en) 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
BR0013952A (en) * 1999-09-15 2002-05-14 Warner Lambert Co Pteridinones as kinase inhibitors
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
PT1244647E (en) 1999-11-05 2006-10-31 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS
JP2001142235A (en) 1999-11-17 2001-05-25 Fuji Denki Gazo Device Kk Electrophotographic photoreceptor
EA006227B1 (en) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS
CA2411084A1 (en) 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
CA2412560C (en) 2000-06-26 2008-12-30 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
JP2004509876A (en) 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 4-amino-quinazoline
KR100600550B1 (en) 2000-10-20 2006-07-13 에자이 가부시키가이샤 Nitrogenous aromatic ring compounds
ATE330956T1 (en) * 2001-04-13 2006-07-15 Pfizer Prod Inc BIZYCLIC SUBSTITUTED 4-AMINOPYRIDOPYRIMIDINE DERIVATIVES
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
CZ294535B6 (en) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyclic compounds based on N6-substituted adenine, processes of their preparation, their use in the preparation of medicaments, cosmetic compositions and growth regulators, as well as pharmaceutical preparations, cosmetic compositions and growth regulators in which these compounds are comprised
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
RS63204A (en) 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
DE60318177T2 (en) 2002-01-23 2008-10-09 Bayer Pharmaceuticals Corp., West Haven RHO-KINASE INHIBITORS
JP2003238561A (en) 2002-02-13 2003-08-27 Fuji Denki Gazo Device Kk Quinomethane compound
BR0308162A (en) 2002-03-01 2004-12-07 Pfizer Thienopyridine indolyl urea derivatives useful as antiangiogenic agents and methods for their use
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
PL378246A1 (en) 2002-11-26 2006-03-20 Pfizer Products Inc. Method of treatment of transplant rejection
CA2513575A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
FR2851248B1 (en) * 2003-02-18 2005-04-08 Aventis Pharma Sa NOVEL DERIVATIVES OF PURINE, PROCESS FOR PREPARING THEM, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
GEP20094664B (en) 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
JP2007502776A (en) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー 6-Substituted anilinopurines as RTK inhibitors
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
ATE412655T1 (en) 2003-08-29 2008-11-15 Pfizer THIENOPYRIDINPHENYLACETAMIDE AND DERIVATIVES THEREOF SUITABLE AS NEW ANTIANGIOGENIC AGENTS
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
CN101337930B (en) 2003-11-11 2010-09-08 卫材R&D管理有限公司 Urea derivative preparation process
UA82577C2 (en) 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
EP1731523A4 (en) * 2004-04-01 2009-08-12 Takeda Pharmaceutical Thiazolopyrimidine derivative
EP1773836B1 (en) 2004-05-27 2012-09-05 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
UA91508C2 (en) * 2004-06-02 2010-08-10 Такеда Фармасьютикал Компани Лимитед Fused heterocyclic compound
CA2569016C (en) * 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
ATE428421T1 (en) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES
ATE501148T1 (en) * 2004-12-14 2011-03-15 Astrazeneca Ab PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTI-TUMOR AGENTS
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090111805A1 (en) * 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
ES2314933T3 (en) * 2005-06-17 2009-03-16 Janssen Pharmaceutica Nv NAFTIRIDINE COMPOUNDS.
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
DE602006015861D1 (en) 2005-12-21 2010-09-09 Abbott Lab ANTIVIRAL CONNECTIONS
ES2395386T3 (en) 2005-12-21 2013-02-12 Abbott Laboratories Antiviral compounds
AU2006330924B2 (en) 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole compounds
GB2453058A (en) * 2006-04-04 2009-03-25 Univ California Kinase antagonists
CN101443009A (en) 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
KR101472600B1 (en) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
EP2103620A1 (en) 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
TWI399380B (en) 2006-12-20 2013-06-21 Abbott Lab Anti-viral compounds
WO2008093855A1 (en) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US20090233937A1 (en) 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP2318377B1 (en) * 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
ES2467109T3 (en) 2008-08-20 2014-06-11 Zoetis Llc Pyrrolo [2,3-d] pyrimidine compounds
AR073501A1 (en) * 2008-09-08 2010-11-10 Boehringer Ingelheim Int PYRIMID DERIVATIVES [5,4-D] PYRIMIDINE INHIBITORS OF THYROSINOQUINASE
KR101126736B1 (en) * 2008-11-27 2012-04-12 주식회사 레고켐 바이오사이언스 Tyrosine kinase inhibitory compounds, isomers thereof or pharmaceutical acceptable salts thereof, and pharmaceutical composition comprising the same
KR102187034B1 (en) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
DE102009005193A1 (en) * 2009-01-20 2010-07-22 Merck Patent Gmbh Novel heterocyclic compounds as MetAP-2 inhibitors
CA2752265A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
JP5572715B2 (en) 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト N-7 substituted purines and pyrazolopyrimidine compounds, compositions and methods of use
CN102711766B (en) 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-substituted purine compounds, compositions and methods of use
MX2012009074A (en) * 2010-02-05 2012-08-23 Pfizer Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors.
KR101677790B1 (en) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent using compounds having kinase inhibitory effect in combination
EA201300283A1 (en) * 2010-08-27 2013-08-30 Мерк Патент Гмбх FUROPYRIDINE DERIVATIVES
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
RU2013144571A (en) 2011-03-04 2015-04-10 Ньюджен Терапьютикс, Инк. ALIN-SUBSTITUTED KINAZAZOLES AND WAYS OF THEIR APPLICATION
RU2580609C2 (en) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer therapeutic agent
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013224420B2 (en) * 2012-02-21 2016-12-15 Merck Patent Gmbh Furopyridine derivatives
JP2015531361A (en) 2012-09-26 2015-11-02 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted indazole-pyrrolopyrimidines useful for the treatment of hyperproliferative diseases
JP2015535833A (en) 2012-09-26 2015-12-17 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted indazole-pyrrolopyrimidines useful in the treatment of hyperproliferative disorders
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
ES2653419T3 (en) 2013-02-01 2018-02-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
WO2014145576A2 (en) * 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PL3177612T3 (en) 2014-08-04 2022-08-08 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
SI3524595T1 (en) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
WO2016136745A1 (en) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for suppressing bitterness of quinoline derivative
KR102662228B1 (en) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CN106831779B (en) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 The noval chemical compound of a kind of jak kinase inhibitor
MX2022007265A (en) 2019-12-20 2022-09-09 Nuevolution As Compounds active towards nuclear receptors.
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
PE20240327A1 (en) 2021-04-13 2024-02-22 Nuvalent Inc HETEROCYCLES WITH AMINO SUBSTITUTION TO TREAT CANCERS WITH EGFR MUTATIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001367A1 (en) * 1992-07-02 1994-01-20 E.I. Du Pont De Nemours And Company A method of obtaining lead and organolead from contaminated media using metal accumulating plants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
JPS58126887A (en) * 1981-09-26 1983-07-28 Takeda Chem Ind Ltd Novel 7-deazapurine derivative
JPS58157790A (en) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd 7-deazapurine derivative and its preparation
JPS60233080A (en) * 1984-05-02 1985-11-19 Takeda Chem Ind Ltd 7-deazapurine derivative
CA1293727C (en) * 1986-08-26 1991-12-31 Catherine Rose Kostlan 9-deazaguanines
NO169490C (en) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PYRROLOPYRIMIDINE DERIVATIVES
CA2067221C (en) * 1989-10-11 1997-04-15 Yasuji Sakuma Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
WO1995001355A1 (en) * 1993-06-30 1995-01-12 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001367A1 (en) * 1992-07-02 1994-01-20 E.I. Du Pont De Nemours And Company A method of obtaining lead and organolead from contaminated media using metal accumulating plants

Also Published As

Publication number Publication date
FI974443A0 (en) 1997-12-05
TR199600474A2 (en) 1996-12-21
AR002746A1 (en) 1998-04-29
DE69531558T2 (en) 2004-03-18
SG45483A1 (en) 1998-01-16
RU2136683C1 (en) 1999-09-10
JP3290666B2 (en) 2002-06-10
DK0831829T3 (en) 2003-12-15
NZ286755A (en) 1998-03-25
CZ164196A3 (en) 1996-12-11
EP0831829B1 (en) 2003-08-20
FI974443A (en) 1997-12-05
AU5479196A (en) 1996-12-19
OA10460A (en) 2002-03-28
SK72996A3 (en) 1997-04-09
NO962386D0 (en) 1996-06-06
EP0831829A4 (en) 1998-11-25
CA2223081C (en) 2001-03-06
CN1141298A (en) 1997-01-29
HUP9601559A3 (en) 1997-07-28
ATE247469T1 (en) 2003-09-15
PT831829E (en) 2003-12-31
ZA964725B (en) 1997-12-08
JPH10508875A (en) 1998-09-02
AP9600805A0 (en) 1996-07-31
PL314641A1 (en) 1996-12-09
CA2223081A1 (en) 1996-12-19
SI9600184A (en) 1997-04-30
MX9709867A (en) 1998-03-31
NO962386L (en) 1996-12-09
HRP960269A2 (en) 1997-08-31
CO4440628A1 (en) 1997-05-07
WO1996040142A1 (en) 1996-12-19
ES2203642T3 (en) 2004-04-16
DE69531558D1 (en) 2003-09-25
MA26409A1 (en) 2004-12-20
BR9602695A (en) 1998-10-06
HUP9601559A2 (en) 1997-02-28
EP0831829A1 (en) 1998-04-01
HU9601559D0 (en) 1996-08-28
IL118487A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
AP637A (en) Heterocyclic ring-fused pyrimidine derivatives.
US6395733B1 (en) Heterocyclic ring-fused pyrimidine derivatives
US6413971B1 (en) Fused bicyclic pyrimidine derivatives
RU2174977C2 (en) Derivatives of 4-(substituted phenylamino)-quinazoline or their pharmaceutically acceptable salts, method of inhibition of receptor tyrosine kinase and pharmaceutical composition
CA2258548C (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US5569658A (en) Tricyclic derivatives
HRP950033A2 (en) Tricyclic compounds capable of inhibiting tryosine kinases of the epidermal growth factor receptor family
PL199615B1 (en) Imidazo[1,2−a]pyridine and pyrazolo[2,3−a]pyridine derivatives
JP2000508657A (en) Irreversible inhibitors of tyrosine kinase
JP2006504632A (en) Inhibitors of checkpoint kinases (Wee1 and Chk1)
JP6943886B2 (en) Condensed pyrimidinopiperidin derivative, and its production method and application